Go to
JCI Insight
Citations to this article
Anna Secher, … , Niels Vrang, Lotte Bjerre Knudsen
Published September 9, 2014
Citation Information: J Clin Invest. 2014;124(10):4473-4488. https://doi.org/10.1172/JCI75276.
Citation Information: J Clin Invest. 2014;124(10):4473-4488. https://doi.org/10.1172/JCI75276.
Abstract
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2 diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully understood how liraglutide induces weight loss or to what degree liraglutide acts directly in the brain. Here, we determined that liraglutide does not activate GLP-1–producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus. Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs. Moreover, labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus. GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in
Authors
Anna Secher, Jacob Jelsing, Arian F. Baquero, Jacob Hecksher-Sørensen, Michael A. Cowley, Louise S. Dalbøge, Gitte Hansen, Kevin L. Grove, Charles Pyke, Kirsten Raun, Lauge Schäffer, Mads Tang-Christensen, Saurabh Verma, Brent M. Witgen, Niels Vrang, Lotte Bjerre Knudsen
Total citations by year
Citation information
Citations to this article (426)
| Title and authors | Publication | Year |
|---|---|---|
|
Exendin-4 improves cerebral ischemia by relaxing microvessels, rapidly increasing cerebral blood flow after reperfusion
Yujie Chen, Lei Wang, Yutong Zhou, Yuguang Wang, Wei Qin, Mingxiao Wang, Bo Liu, Qian Tian, Zhihao Lang, Hui Shen, Chen Zheng |
Basic research in cardiology | 2025 |
|
Mechanisms and pharmacotherapy of cancer cachexia‐associated anorexia
Sato R, da Fonseca GW, das Neves W, von Haehling S |
Pharmacology Research & Perspectives | 2025 |
|
Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics
Liang J, Liu H, Lv G, Chen X, Yang Z, Hu K, Sun H |
Lipids in Health and Disease | 2025 |
|
GLP-1 and the Neurobiology of Eating Control: Recent Advances
Jones LA, Brierley DI |
Endocrinology | 2025 |
|
Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial)
Klausen MK, Kuzey T, Pedersen JN, Justesen SK, Rasmussen L, Knorr UB, Mason G, Ekstrøm CT, Holst JJ, Koob G, Benveniste H, Volkow ND, Knudsen GM, Vilsbøll T, Fink-Jensen A |
BMJ Open | 2025 |
|
Effects of GLP‐1 Receptor Agonists in Alcohol Use Disorder
Klausen MK, Knudsen GM, Vilsbøll T, Fink\u2010Jensen A |
Basic & Clinical Pharmacology & Toxicology | 2025 |
|
Glucagon-like peptide-1 (GLP-1) links ingestion, homeostasis, and the heart
Krieger JP, Daniels D, Lee S, Mastitskaya S, Langhans W |
Comprehensive Physiology | 2025 |
|
Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
He X, Zhao W, Li P, Zhang Y, Li G, Su H, Lu B, Pang Z |
Frontiers in Pharmacology | 2025 |
|
Integration of Glucagon-Like Peptide 1 Receptor Actions Through the Central Amygdala
Duran M, Willis JR, Dalvi N, Fokakis Z, Virkus SA, Hardaway JA |
Endocrinology | 2025 |
|
Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity
Zhang J, Wei J, Lai W, Sun J, Bai Y, Cao H, Guo J, Su Z |
International Journal of Molecular Sciences | 2025 |
|
Upcoming drug targets for kidney protective effects in chronic kidney disease
Nardone M, Yau K, Kugathasan L, Odutayo A, Mohsen M, Ouimet JP, Sridhar VS, Cherney DZ |
Nephrology Dialysis Transplantation | 2025 |
|
Gut Microbiome Regulation of Gut Hormone Secretion
Chao J, Coleman RA, Keating DJ, Martin AM |
Endocrinology | 2025 |
|
Fam163a knockdown and mitochondrial stress in the arcuate nucleus of hypothalamus reduce AgRP neuron activity and differentially regulate mitochondrial dynamics in mice
Erdogan CS, Yavuz Y, Ozgun HB, Bilgin VA, Agus S, Kalkan UF, Yilmaz B |
Acta Physiologica (Oxford, England) | 2025 |
|
A comprehensive spatio-cellular map of the human hypothalamus
Tadross JA, Steuernagel L, Dowsett GK, Kentistou KA, Lundh S, Porniece M, Klemm P, Rainbow K, Hvid H, Kania K, Polex-Wolf J, Knudsen LB, Pyke C, Perry JR, Lam BY, Brüning JC, Yeo GS |
Nature | 2025 |
|
Glucose-dependent insulinotropic polypeptide (GIP)
Müller TD, Adriaenssens A, Ahrén B, Blüher M, Birkenfeld AL, Campbell JE, Coghlan MP, D'Alessio D, Deacon CF, DelPrato S, Douros JD, Drucker DJ, Figueredo Burgos NS, Flatt PR, Finan B, Gimeno RE, Gribble FM, Hayes MR, Hölscher C, Holst JJ, Knerr PJ, Knop FK, Kusminski CM, Liskiewicz A, Mabilleau G, Mowery SA, Nauck MA, Novikoff A, Reimann F, Roberts AG, Rosenkilde MM, Samms RJ, Scherer PE, Seeley RJ, Sloop KW, Wolfrum C, Wootten D, DiMarchi RD, Tschöp MH |
Molecular Metabolism | 2025 |
|
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss AB, Gulkarov S, Lau R, Klek SP, Srivastava A, Renna HA, De Leon J |
Biomolecules | 2025 |
|
Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review
Luna Ceron E, Reddy SD, Kattamuri L, Muvva DM, Chozet L, Bright T |
Journal of Brown Hospital Medicine | 2025 |
|
Arrestin‐independent internalization of the GLP‐1 receptor is facilitated by a GRK, clathrin, and caveolae‐dependent mechanism
Moo EV, Møller TC, Sørensen FA, Inoue A, Bräuner\u2010Osborne H |
The Febs Journal | 2025 |
|
On the Pleiotropic Actions of Glucagon-like Peptide-1 in Its Regulation of Homeostatic and Hedonic Feeding
Sayers S, Wagner E |
International Journal of Molecular Sciences | 2025 |
|
Oppositely biased glucagon‐like peptide‐1 receptor agonism does not differentially affect lipid metabolism in APOE*3‐Leiden CETP mice
Modder M, Tomas A, Afkir S, Pronk AC, Streefland TC, Lalai RA, van Eenige R, Rensen PC, Jones B, Kooijman S |
Diabetes, Obesity & Metabolism | 2025 |
|
Incretin-based therapeutics for the treatment of neurodegenerative diseases.
Vear A, Heneka MT, Clemmensen C |
Nature metabolism | 2025 |
|
GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice.
Gutgesell RM, Khalil A, Liskiewicz A, Maity-Kumar G, Novikoff A, Grandl G, Liskiewicz D, Coupland C, Karaoglu E, Akindehin S, Castelino R, Curion F, Liu X, Garcia-Caceres C, Cebrian-Serrano A, Douros JD, Knerr PJ, Finan B, DiMarchi RD, Sloop KW, Samms RJ, Theis FJ, Tschöp MH, Müller TD |
Nature metabolism | 2025 |
|
Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review.
West J, Li M, Wong S, Le GH, Teopiz KM, Valentino K, Dri CE, McIntyre RS |
Neurology and therapy | 2025 |
|
Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.
Arrowaili A |
Obesity surgery | 2025 |
|
Non-caloric sweetener effects on brain appetite regulation in individuals across varying body weights.
Chakravartti SP, Jann K, Veit R, Liu H, Yunker AG, Angelo B, Monterosso JR, Xiang AH, Kullmann S, Page KA |
Nature metabolism | 2025 |
|
Hallmarks of Appetite: A Comprehensive Review of Hunger, Appetite, Satiation, and Satiety.
Garutti M, Sirico M, Noto C, Foffano L, Hopkins M, Puglisi F |
Current obesity reports | 2025 |
|
Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies
Park JS, Kim KS, Choi HJ |
Diabetes & Metabolism Journal | 2025 |
|
The effect of GLP-1 receptor agonists on cardiac remodeling in heart failure patients with preserved and reduced ejection fraction: a systematic review and meta-analysis.
Siddiqui HF, Waqas SA, Batool RM, Salim H, Minhas AMK, Hasni SF, Alsaid A, Sannino A, Afzal AM, Khan MS |
Heart failure reviews | 2025 |
|
Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer’s Disease
Urkon M, Ferencz E, Szász JA, Szabo MI, Orbán-Kis K, Szatmári S, Nagy EE |
Pharmaceuticals | 2025 |
|
Smoking, Obesity, and Post-Cessation Weight Gain: Neurobiological Intersection and Treatment Recommendations
Golden A, Davis JM |
Journal of Multidisciplinary Healthcare | 2025 |
|
Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review
Al Lawati A, Alhabsi A, Rahul R, Savino ML, Alwahaibi H, Das S, Al Lawati H |
Diseases | 2025 |
|
Progress and challenges in obesity pharmacotherapy: semaglutide as a milestone.
Ferrara F, Bazzani D, Crivelli B, Danieli E, Gazzola P, Guarnieri G, Handschin G, Lauria C, Marchetti C, Sbraga E, Zero C, Zovi A, Langella R, Parati C |
Naunyn-Schmiedeberg's archives of pharmacology | 2025 |
|
Central neuropeptides as key modulators of astrocyte function in neurodegenerative and neuropsychiatric disorders.
Yang MJ, Jia M, Cai M, Feng X, Huang LN, Yang JJ |
Psychopharmacology | 2025 |
|
Liraglutide improves depressive and cognitive deficits in a high-fat diet rat model of obesity: the role of hippocampal autophagy and the PI3K/Akt/mTOR pathway.
Magdy YM, Kamar SA, Habib MZ, Rady HY, Rabei MR, Khedr S |
Psychopharmacology | 2025 |
|
The GLP-1 journey: from discovery science to therapeutic impact.
Drucker DJ |
Journal of Clinical Investigation | 2024 |
|
Nutrient Combinations Sensed by L-Cell Receptors Potentiate GLP-1 Secretion
Sodum N, Mattila O, Sharma R, Kamakura R, Lehto VP, Walkowiak J, Herzig KH, Raza GS |
International journal of molecular sciences | 2024 |
|
GLP-1R-positive neurons in the lateral septum mediate the anorectic and weight-lowering effects of liraglutide
Zijun Chen, Xiaofei Deng, Cuijie Shi, Haiyang Jing, Jiafeng Zhong, Gaowei Chen, Yunlong Xu, Yixiao Luo, Yingjie Zhu |
Journal of Clinical Investigation | 2024 |
|
Obesity and the kidney: mechanistic links and therapeutic advances.
Yau K, Kuah R, Cherney DZI, Lam TKT |
Nature reviews. Endocrinology | 2024 |
|
Satiety: a gut-brain-relationship.
Barakat GM, Ramadan W, Assi G, Khoury NBE |
The journal of physiological sciences : JPS | 2024 |
|
Wiring the Brain for Wellness: Sensory Integration in Feeding and Thermogenesis: A Report on Research Supported by Pathway to Stop Diabetes
Riera CE |
Diabetes | 2024 |
|
GLP-1 and PYY for the treatment of obesity: a pilot study on the use of agonists and antagonists in diet-induced rats
Oertel M, Ziegler CG, Kohlhaas M, Nickel A, Kloock S, Maack C, Sequeira V, Fassnacht M, Dischinger U |
Endocrine Connections | 2024 |
|
Evaluating the effectiveness and underlying mechanisms of incretin-based treatments for hypothalamic obesity: A narrative review
Chartoumpekis DV, Habeos EE, Psilopanagioti A |
2024 | |
|
GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review
Aoun L, Almardini S, Saliba F, Haddadin F, Mourad O, Jdaidani J, Morcos Z, Al Saidi I, Bou Sanayeh E, Saliba S, Almardini M, Zaidan J |
Journal of Clinical & Translational Endocrinology | 2024 |
|
Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities.
Bettadapura S, Dowling K, Jablon K, Al-Humadi AW, le Roux CW |
International Journal of Obesity | 2024 |
|
Incretin hormones and pharmacomimetics rapidly inhibit AgRP neuron activity to suppress appetite
McMorrow HE, Lorch CM, Hayes NW, Fleps SW, Frydman JA, Xia JL, Samms RJ, Beutler LR |
2024 | |
|
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature
Chrysavgis LG, Kazanas S, Bafa K, Rozani S, Koloutsou ME, Cholongitas E |
International journal of molecular sciences | 2024 |
|
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management.
Son JW, Lim S |
2024 | |
|
Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study
Zakaria H, Alshehhi S, Caccelli M, Ozkan C, Kattan J, Jafaar Z, Laborte R, Aleabova S, Almarzooqi N, Hashemi A, Almarzooqi I |
2024 | |
|
Endocrine features of Prader-Willi syndrome: a narrative review focusing on genotype-phenotype correlation
Madeo SF, Zagaroli L, Vandelli S, Calcaterra V, Crinò A, De Sanctis L, Faienza MF, Fintini D, Guazzarotti L, Licenziati MR, Mozzillo E, Pajno R, Scarano E, Street ME, Wasniewska M, Bocchini S, Bucolo C, Buganza R, Chiarito M, Corica D, Di Candia F, Francavilla R, Fratangeli N, Improda N, Morabito LA, Mozzato C, Rossi V, Schiavariello C, Farello G, Iughetti L, Salpietro V, Salvatoni A, Giordano M, Grugni G, Delvecchio M |
Frontiers in Endocrinology | 2024 |
|
GLP-1-directed NMDA receptor antagonism for obesity treatment.
Petersen J, Ludwig MQ, Juozaityte V, Ranea-Robles P, Svendsen C, Hwang E, Kristensen AW, Fadahunsi N, Lund J, Breum AW, Mathiesen CV, Sachs L, Moreno-Justicia R, Rohlfs R, Ford JC, Douros JD, Finan B, Portillo B, Grose K, Petersen JE, Trauelsen M, Feuchtinger A, DiMarchi RD, Schwartz TW, Deshmukh AS, Thomsen MB, Kohlmeier KA, Williams KW, Pers TH, Frølund B, Strømgaard K, Klein AB, Clemmensen C |
Nature | 2024 |
|
Neuroanatomical dissection of the MC3R circuitry regulating energy rheostasis
Possa-Paranhos IC, Butts J, Pyszka E, Nelson C, Cho D, Sweeney P |
2024 | |
|
A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity
Abdullah bin Ahmed I |
Journal of Obesity | 2024 |
|
Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges
Xie C, Alkhouri N, Elfeki MA |
World journal of hepatology | 2024 |
|
Novel therapeutic strategy for obesity through the gut microbiota-brain axis: A review article
Kardan R, Hemmati J, Nazari M, Ahmadi A, Asghari B, Azizi M, Khaledi M, Arabestani MR |
Caspian Journal of Internal Medicine | 2024 |
|
Genetics, pharmacotherapy, and dietary interventions in childhood obesity
Son JE |
2024 | |
|
Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss
Buller S, Blouet C |
American journal of physiology. Endocrinology and metabolism | 2024 |
|
Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus
Abiola JO, Oluyemi AA, Idowu OT, Oyinloye OM, Ubah CS, Owolabi OV, Somade OT, Onikanni SA, Ajiboye BO, Osunsanmi FO, Nash O, Omotuyi OI, Oyinloye BE |
Pharmaceuticals | 2024 |
|
Unlocking the Potential: Semaglutide’s Impact on Alzheimer’s and Parkinson’s Disease in Animal Models
Meca AD, Boboc IK, Mititelu-Tartau L, Bogdan M |
Current issues in molecular biology | 2024 |
|
Topography of the GLP-1/GLP-1 receptor system in the spinal cord of male mice
Ruska Y, Csibi A, Dorogházi B, Szilvásy-Szabó A, Mohácsik P, Környei Z, Dénes Á, Kádár A, Puskár Z, Hrabovszky E, Gereben B, Wittmann G, Fekete C |
Scientific Reports | 2024 |
|
Building the Glucagon-Like Peptide-1 Receptor Brick by Brick: Revisiting a 1993 Diabetes Classic by Thorens et al.
Thorens B, Hodson DJ |
Diabetes | 2024 |
|
Hypothalamic GABAergic Neurons Expressing Cellular Retinoic Acid Binding Protein 1 (CRABP1) Are Sensitive to Metabolic Status and Liraglutide in Male Mice
Lavoie O, Turmel A, Mattoon P, Desrosiers WJ, Plamondon J, Michael NJ, Caron A |
Neuroendocrinology | 2024 |
|
Laser Acupuncture versus Liraglutide in Treatment of Obesity: A Multi-Institutional Retrospective Cohort Study
Yu WL, Liao YN, Yang TH, Yang CW, Kao TI, Lee PW, Hsu CY, Huang JL, Huang YT, Chen HY |
Healthcare | 2024 |
|
All GLP-1 Agonists Should, Theoretically, Cure Alzheimer’s Dementia but Dulaglutide Might Be More Effective Than the Others
Fessel J |
Journal of Clinical Medicine | 2024 |
|
Impacts of different pancreatic resection ranges on endocrine function in Suncus murinus
Li RJ, Yang T, Zeng YH, Natsuyama Y, Ren K, Li J, Nagakawa Y, Yi SQ |
World journal of gastrointestinal surgery | 2024 |
|
Machine-Learning-Guided Peptide Drug Discovery: Development of GLP-1 Receptor Agonists with Improved Drug Properties.
Nielsen JC, Hjo Rringgaard C, Nygaard MMR, Wester A, Elster L, Porsgaard T, Mikkelsen RB, Rasmussen S, Madsen AN, Schlein M, Vrang N, Rigbolt K, Dalbo Ge LS |
Journal of Medicinal Chemistry | 2024 |
|
Populations of Hindbrain Glucagon-Like Peptide 1 (GLP1) Neurons That Innervate the Hypothalamic PVH, Thalamic PVT, or Limbic Forebrain BST Have Axon Collaterals That Reach All Central Regions Innervated by GLP1 Neurons
Randolph AB, Zheng H, Rinaman L |
Journal of Neuroscience | 2024 |
|
Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?
Lafferty RA, Flatt PR, Gault VA, Irwin N |
The Journal of endocrinology | 2024 |
|
Semaglutide treatment of hypothalamic obesity - a real-life data study.
Svendstrup M, Rasmussen AK, Kistorp C, Klose M, Andreassen M |
Pituitary | 2024 |
|
Dissociable hindbrain GLP1R circuits for satiety and aversion.
Huang KP, Acosta AA, Ghidewon MY, McKnight AD, Almeida MS, Nyema NT, Hanchak ND, Patel N, Gbenou YSK, Adriaenssens AE, Bolding KA, Alhadeff AL |
Nature | 2024 |
|
Rebalancing the Gut: Glucagon-Like Peptide-1 Agonists as a Strategy for Obesity and Metabolic Health
Singh K, Aulakh SK, Nijjar GS, Singh S, Sandhu AP, Luthra S, Tanvir F, Kaur Y, Singla A, Kaur MS |
Cureus | 2024 |
|
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.
Holst JJ |
Nature metabolism | 2024 |
|
Alx3 deficiency disrupts energy homeostasis, alters body composition, and impairs hypothalamic regulation of food intake
Mirasierra M, Fernández-Pérez A, Lizarbe B, Keiran N, Ruiz-Cañas L, Casarejos MJ, Cerdán S, Vendrell J, Fernández-Veledo S, Vallejo M |
Cellular and Molecular Life Sciences: CMLS | 2024 |
|
Improved leptin sensitivity and increased soluble leptin receptor concentrations may underlie the additive effects of combining PYY [, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ] and exendin-4 on body weight lowering in diet-induced obese mice
Wulff BS, Kuhre RE, Selvaraj M, Rehfeld JF, Niss K, Fels JJ, Anna S, Raun K, Gerstenberg MK |
Heliyon | 2024 |
|
Doublecortin-like knockdown in mice attenuates obesity by stimulating energy expenditure in adipose tissue.
Modder M, Coomans CP, Saaltink DJ, Tersteeg MMH, Hoogduin J, Scholten L, Pronk ACM, Lalai RA, Boelen A, Kalsbeek A, Rensen PCN, Vreugdenhil E, Kooijman S |
Scientific reports | 2024 |
|
Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs
Le R, Nguyen MT, Allahwala MA, Psaltis JP, Marathe CS, Marathe JA, Psaltis PJ |
Journal of Clinical Medicine | 2024 |
|
Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance
De Fano M, Malara M, Vermigli C, Murdolo G |
International Journal of Molecular Sciences | 2024 |
|
The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension
Lee HY, Ko SH, Park S, Kim K, Kim SY, Cho IJ, Cho EJ, Kim HC, Park JH, Ryu SK, Moon MK, Ihm SH |
Clinical Hypertension | 2024 |
|
Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs).
Weirath NA, Haskell-Luevano C |
ACS pharmacology & translational science | 2024 |
|
QnAs with Svetlana Mojsov, Joel Habener, and Lotte Bjerre Knudsen: Winners of the 2024 Lasker~DeBakey Clinical Medical Research Award
Nair P |
Proceedings of the National Academy of Sciences of the United States of America | 2024 |
|
Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery: a multi-ancestry study in 10 960 individuals from 9 biobanks
German J, Cordioli M, Tozzo V, Urbut S, Arumäe K, Smit RA, Lee J, Li JH, Janucik A, Ding Y, Akinkuolie A, Heyne H, Eoli A, Saad C, Al-Sarraj Y, Abdel-latif R, Barry A, Wang Z, Natarajan P, Ripatti S, Philippakis A, Szczerbinski L, Pasaniuc B, Mbarek H, Loos RJ, Vainik U, Ganna A |
medRxiv | 2024 |
|
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review
Hamed K, Alosaimi MN, Ali BA, Alghamdi A, Alkhashi T, Alkhaldi SS, Altowarqi NA, Alzahrani H, Alshehri AM, Alkhaldi RK, Alqahtani KW, Alharbi NH, Alhulayfi HF, Sharifi SY, Dighriri IM |
Cureus | 2024 |
|
Impaired brain glucose metabolism in glucagon-like peptide-1 receptor knockout mice.
Li H, Fang Y, Wang D, Shi B, Thompson GJ |
Nutrition & diabetes | 2024 |
|
Scalable Hypothalamic Arcuate Neuron Differentiation from Human Pluripotent Stem Cells Suitable for Modeling Metabolic and Reproductive Disorders.
Jovanovic VM, Narisu N, Bonnycastle LL, Tharakan R, Mesch KT, Glover HJ, Yan T, Sinha N, Sen C, Castellano D, Yang S, Blivis D, Ryu S, Bennett DF, Rosales-Soto G, Inman J, Ormanoglu P, LeClair CA, Xia M, Schneider M, Hernandez-Ochoa EO, Erdos MR, Simeonov A, Chen S, Collins FS, Doege CA, Tristan CA |
bioRxiv : the preprint server for biology | 2024 |
|
Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.
Wen J, Nadora D, Bernstein E, How-Volkman C, Truong A, Akhtar M, Prakash NA, Puglisi J, Frezza E |
Cureus | 2024 |
|
Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action.
Bykova A, Serova M, Chashkina M, Kosharnaya R, Salpagarova Z, Andreev D, Giverts I |
Cardiac failure review | 2024 |
|
Review on the role of hypothalamic astrocytes in the neuroendocrine control of metabolism
Farhadi Z, Khaksari M, Alivirdiloo V, Mehrjerdi FZ, Alborzi N, Baktash KB, Rezvani ME |
Journal of Diabetes and Metabolic Disorders | 2024 |
|
Effectiveness of glucagon-like peptide-1 receptor agonists for reduction of body mass index and blood glucose control in patients with type 2 diabetes mellitus and obesity: A retrospective cohort study and difference-in-difference analysis
Siriyotha S, Anothaisintawee T, Looareesuwan P, Nimitphong H, McKay GJ, Attia J, Thakkinstian A |
BMJ Open | 2024 |
|
Does Incretin Agonism Have Sustainable Efficacy?
Janket SJ, Chatanaka MK, Sohaei D, Tamimi F, Meurman JH, Diamandis EP |
Cells | 2024 |
|
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Sidrak WR, Kalra S, Kalhan A |
Indian Journal of Endocrinology and Metabolism | 2024 |
|
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh RJ, Plummer MP, Marathe CS, Umapathysivam MM, Quast DR, Rayner CK, Jones KL, Wu T, Horowitz M, Nauck MA |
The Journal of Clinical Endocrinology and Metabolism | 2024 |
|
Old and new anti-obesity drugs
Dodangeh S, Hasani-Ranjbar S |
Journal of Diabetes and Metabolic Disorders | 2024 |
|
Insights into the Neurobiology of Weight Loss after Bariatric Surgery and GLP-1R Agonists
Cook TM, Fuller KN, Sandoval DA |
Neuropharmacology | 2024 |
|
Medial hypothalamic MC3R signalling regulates energy rheostasis in adult mice
Possa\u2010Paranhos IC, Butts J, Pyszka E, Nelson C, Congdon S, Cho D, Sweeney P |
The Journal of Physiology | 2024 |
|
GLP-1 and Its Analogs: Does Sex Matter?
Börchers S, Skibicka KP |
Endocrinology | 2024 |
|
Incretin hormones and Obesity
Alcaino C, Reimann F, Gribble FM |
The Journal of physiology | 2024 |
|
Hunting for heroes: Brain neurons mediating GLP-1R agonists in obesity treatment
Cao Y, Tong Q |
Obesity medicine | 2024 |
|
The hypothalamus as the central regulator of energy balance and its impact on current and future obesity treatments
Bombassaro B, Araujo EP, Velloso LA |
Archives of Endocrinology and Metabolism | 2024 |
|
Novel neural pathways targeted by GLP-1R agonists and bariatric surgery
Hankir MK, Lutz TA |
Pflugers Archiv | 2024 |
|
Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss
Wean J, Kowalsky AH, Laker R, Will S, Drucker DJ, Rhodes CJ, Seeley RJ |
Molecular Metabolism | 2024 |
|
GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans
Kim KS, Park JS, Hwang E, Park MJ, Shin HY, Lee YH, Kim KM, Gautron L, Godschall E, Portillo B, Grose K, Jung SH, Baek SL, Yun YH, Lee D, Kim E, Ajwani J, Yoo SH, Güler AD, Williams KW, Choi HJ |
Science (New York, N.Y.) | 2024 |
|
Molecular connectomics reveals a glucagon-like peptide 1-sensitive neural circuit for satiety.
Webster AN, Becker JJ, Li C, Schwalbe DC, Kerspern D, Karolczak EO, Bundon CB, Onoharigho RA, Crook M, Jalil M, Godschall EN, Dame EG, Dawer A, Belmont-Rausch DM, Pers TH, Lutas A, Habib N, Güler AD, Krashes MJ, Campbell JN |
Nature metabolism | 2024 |
|
Anorexigenic and anti-inflammatory signaling pathways of semaglutide via the microbiota-gut--brain axis in obese mice.
da Silva RS, de Paiva IHR, Mendonça IP, de Souza JRB, Lucena-Silva N, Peixoto CA |
Inflammopharmacology | 2024 |
|
Glucose-dependent insulinotropic polypeptide receptor (GIPR)-expressing neurons in the hypothalamus and the dorsal vagal complex employ distinct mechanisms to affect feeding behaviour
Alice Adriaenssens, Johannes Broichhagen, Anne de Bray, Julia Ast, Annie Hasib, Ben Jones, Alejandra Tomas, Orla Woodward, Jo Lewis, Kimberley El, Canqi Cui, Norio Harada, Nobuya Inagaki, Jonathan Campbell, David Hodson, Ricardo Samms, Fiona Gribble, Frank Reimann |
JCI Insight | 2023 |
|
Revealing the tissue-level complexity of endogenous glucagon-like peptide-1 receptor expression and signaling
Ast J, Nasteska D, Fine NH, Nieves DJ, Koszegi Z, Lanoiselée Y, Cuozzo F, Viloria K, Bacon A, Luu NT, Newsome PN, Calebiro D, Owen DM, Broichhagen J, Hodson DJ |
Nature Communications | 2023 |
|
Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis
Yeh TL, Tsai MC, Tsai WH, Tu YK, Chien KL |
PloS one | 2023 |
|
Liver fibroblast growth factor 21 (FGF21) is required for the full anorectic effect of the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets
Thao DV Le, Payam Fathi, Amanda Watters, Blair Ellis, Nadejda Bozadjieva-Kramer, Misty Perez, Andrew Sullivan, Jesse Rose, Laurie Baggio, Jacqueline Koehler, Jennifer Brown, Michelle Bales, Kaitlyn Nwaba, Jonathan Campbell, Daniel Drucker, Matthew Potthoff, Randy Seeley, Julio Ayala |
Molecular Metabolism | 2023 |
|
Interaction between gut microbiota and sex hormones and their relation to sexual dimorphism in metabolic diseases
Santos-Marcos JA, Mora-Ortiz M, Tena-Sempere M, Lopez-Miranda J, Camargo A |
Biology of sex differences | 2023 |
|
Osmoadaptive GLP-1R signalling in hypothalamic neurones inhibits antidiuretic hormone synthesis and release
Greenwood MP, Greenwood M, Bárez-López S, Hawkins JW, Short K, Tatovic D, Murphy D |
Molecular Metabolism | 2023 |
|
Multimodal 3D Mouse Brain Atlas Framework with the Skull-Derived Coordinate System.
Perens J, Salinas CG, Roostalu U, Skytte JL, Gundlach C, Hecksher-Sørensen J, Dahl AB, Dyrby TB |
Neuroinformatics | 2023 |
|
Successful naltrexone-bupropion treatment after several treatment failures in a patient with severe monogenic obesity
Welling MS, Mohseni M, van der Valk ES, van Hagen JM, Burgerhart JS, van Haelst MM, van Rossum EF |
iScience | 2023 |
|
The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials
Aldawsari M, Almadani FA, Almuhammadi N, Algabsani S, Alamro Y, Aldhwayan M |
2023 | |
|
Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
Zaffina I, Pelle MC, Armentaro G, Giofrè F, Cassano V, Sciacqua A, Arturi F |
Frontiers in Endocrinology | 2023 |
|
Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC)
Volpe M, Gallo G |
Frontiers in Cardiovascular Medicine | 2023 |
|
Obesity in Adults: Position Statement of Polish Association for the Study on Obesity, Polish Association of Endocrinology, Polish Association of Cardiodiabetology, Polish Psychiatric Association, Section of Metabolic and Bariatric Surgery of the Association of Polish Surgeons, and the College of Family Physicians in Poland.
Olszanecka-Glinianowicz M, Mazur A, Chudek J, Kos-Kudła B, Markuszewski L, Dudek D, Major P, Małczak P, Tarnowski W, Jaworski P, Tomiak E |
Nutrients | 2023 |
|
GLP-1 enhances hyperpolarization-activated currents of mouse cerebellar Purkinje cell in vitro.
Liu Y, Cao LX, Wang WY, Piao YR, Wang JY, Chu CP, Bing YH, Qiu DL |
Frontiers in molecular neuroscience | 2023 |
|
RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis.
Jamaluddin A, Gorvin CM |
Journal of molecular endocrinology | 2023 |
|
Glucagon-like peptide-1 facilitates cerebellar parallel fiber glutamate release through PKA signaling in mice in vitro
Wang XY, Liu Y, Cao LX, Li YZ, Wan P, Qiu DL |
Scientific Reports | 2023 |
|
Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
Iijima T, Shibuya M, Ito Y, Terauchi Y |
Journal of Diabetes Investigation | 2023 |
|
GLP-1 Increases Circulating Leptin Levels in Truncal Vagotomized Rats.
Morais T, Pereira SS, Andrade S, Neves D, Guimarães M, Nora M, Carreira MC, Casanueva FF, Monteiro MP |
Biomedicines | 2023 |
|
Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
Wibawa ID, Mariadi IK, Somayana G, Krisnawardani Kumbara CI, Sindhughosa DA |
World journal of diabetes | 2023 |
|
Position statement on nutrition therapy for overweight and obesity: nutrition department of the Brazilian association for the study of obesity and metabolic syndrome (ABESO-2022).
Pepe RB, Lottenberg AM, Fujiwara CTH, Beyruti M, Cintra DE, Machado RM, Rodrigues A, Jensen NSO, Caldas APS, Fernandes AE, Rossoni C, Mattos F, Motarelli JHF, Bressan J, Saldanha J, Beda LMM, Lavrador MSF, Del Bosco M, Cruz P, Correia PE, Maximino P, Pereira S, Faria SL, Piovacari SMF |
Diabetology & metabolic syndrome | 2023 |
|
Impact of short and long exposure to cafeteria diet on food intake and white adipose tissue lipolysis mediated by glucagon-like peptide 1 receptor
Mattar P, Jaque C, Teske JA, Morselli E, Kerr B, Cortés V, Baudrand R, Perez-Leighton CE |
Frontiers in Endocrinology | 2023 |
|
Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth.
Berman C, Vidmar AP, Chao LC |
2023 | |
|
Targeting the central melanocortin system for the treatment of metabolic disorders.
Sweeney P, Gimenez LE, Hernandez CC, Cone RD |
Nature reviews. Endocrinology | 2023 |
|
New Long-Acting [89Zr]Zr-DFO GLP-1 PET Tracers with Increased Molar Activity and Reduced Kidney Accumulation
Wilbs J, Raavé R, Boswinkel M, Glendorf T, Rodríguez D, Fernandes EF, Heskamp S, Bjørnsdottir I, Gustafsson MB |
Journal of Medicinal Chemistry | 2023 |
|
Chronic Semaglutide Treatment in Rats Leads to Daily Excessive Concentration-Dependent Sucrose Intake
Cawthon CR, Blonde GD, Nisi AV, Bloomston HM, Krubitski B, le Roux CW, Spector AC |
Journal of the Endocrine Society | 2023 |
|
Neurochemical Basis of Inter-Organ Crosstalk in Health and Obesity: Focus on the Hypothalamus and the Brainstem
Haspula D, Cui Z |
Cells | 2023 |
|
Effects of a long-acting secretin peptide analog alone and in combination with a GLP-1R agonist in a diet-induced obesity mouse model
Loeffler M, Klepac K, Baljuls A, Hamilton B, Mayer-Wrangowski S, Haebel P, Zimmermann T |
Molecular Metabolism | 2023 |
|
Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide.
Sherwin M, Hamburger J, Katz D, DeMaria S Jr |
2023 | |
|
Neural Progenitor Cells and the Hypothalamus
Makrygianni EA, Chrousos GP |
Cells | 2023 |
|
Recent advancements in pharmacological strategies to modulate energy balance for combating obesity
Pati B, Sendh S, Sahu B, Pani S, Jena N, Bal NC |
2023 | |
|
GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
Xiang J, Qin L, Zhong J, Xia N, Liang Y |
2023 | |
|
Clinical and Therapeutic Implications of Male Obesity.
Lenart-Lipińska M, Łuniewski M, Szydełko J, Matyjaszek-Matuszek B |
Journal of Clinical Medicine | 2023 |
|
Novel Treatments for Obesity: Implications for Cancer Prevention and Treatment
Cuttica CM, Briata IM, DeCensi A |
Nutrients | 2023 |
|
The locus coeruleus contributes to the anorectic, nausea, and autonomic physiological effects of glucagon-like peptide-1
Fortin SM, Chen JC, Petticord MC, Ragozzino FJ, Peters JH, Hayes MR |
Science Advances | 2023 |
|
Applications of Enteroendocrine Cells (EECs) Hormone: Applicability on Feed Intake and Nutrient Absorption in Chickens
Lee J, Kim WK |
2023 | |
|
Angiotensin AT1A receptor signal switching in Agouti-related peptide neurons mediates metabolic rate adaptation during obesity
Balapattabi K, Yavuz Y, Jiang J, Deng G, Mathieu NM, Ritter ML, Opichka MA, Reho JJ, McCorvy JD, Nakagawa P, Morselli LL, Mouradian GC Jr, Atasoy D, Cui H, Hodges MR, Sigmund CD, Grobe JL |
Cell Reports | 2023 |
|
Enteroendocrine cell regulation of the gut-brain axis
Barton JR, Londregan AK, Alexander TD, Entezari AA, Covarrubias M, Waldman SA |
Frontiers in neuroscience | 2023 |
|
Molecular Connectomics Reveals a Glucagon-Like Peptide 1 Sensitive Neural Circuit for Satiety
Webster AN, Becker JJ, Li C, Schwalbe DC, Kerspern D, Karolczak EO, Godschall EN, Belmont-Rausch DM, Pers TH, Lutas A, Habib N, Güler AD, Krashes MJ, Campbell JN |
2023 | |
|
GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
Złotek M, Kurowska A, Herbet M, Piątkowska-Chmiel I |
Biomedicines | 2023 |
|
Sex Differences in the Preventive Effect of Cardiovascular and Metabolic Therapeutics on Dementia
Choi SA, Jee HJ, Bormate KJ, Kim Y, Jung YS |
Biomolecules & therapeutics | 2023 |
|
Glucagon-like peptide-1 receptor activation stimulates PKA-mediated phosphorylation of Raptor and this contributes to the weight loss effect of liraglutide.
Le TDV, Liu D, Besing GK, Raghavan R, Ellis BJ, Ceddia RP, Collins S, Ayala JE |
eLife | 2023 |
|
Unlocking Therapeutic Synergy: Tailoring Drugs for Comorbidities such as Depression and Diabetes through Identical Molecular Targets in Different Cell Types.
Coppola T, Daziano G, Legroux I, Béraud-Dufour S, Blondeau N, Lebrun P |
Cells | 2023 |
|
Adipose Tissue, Non-Communicable Diseases, and Physical Exercise: An Imperfect Triangle.
Monsalve FA, Delgado-López F, Fernández-Tapia B, González DR |
International journal of molecular sciences | 2023 |
|
Evaluating the Clinical Effectiveness and Safety of Semaglutide in Individuals with Uncontrolled Type 2 Diabetes. Real-World Evidence from Saudi Arabia: The Observational, Multicenter, 15-Month EVOLUTION Study.
Alsheikh A, Alshehri A, Alzahrani S, Jammah AA, Alqahtani F, Alotaibi M, Aldahash R, Alhozali AM, Alsabaan F, Almehthel M, Aljuhani N, Aldabeis A, Alamri M, Maghawry W, Alzaman N, Alshaikh A, M Alnozha O, Issak ER, Alsifri S |
2023 | |
|
Arcuate Nucleus of the Hypothalamus: Anatomy, Physiology, and Diseases.
Song J, Choi SY |
Experimental Neurobiology | 2023 |
|
Leptin Reduction as a Required Component for Weight Loss
Zhao S, Li N, Xiong W, Li G, He S, Zhang Z, Zhu Q, Jiang N, Ikejiofor C, Zhu Y, Wang MY, Han X, Zhang N, Solis-Herrera C, Kusminski C, An Z, Elmquist JK, Scherer PE |
Diabetes | 2023 |
|
Newer pharmacological interventions directed at gut hormones for obesity.
Camilleri M, Acosta A |
British Journal of Pharmacology | 2023 |
|
Current and emerging medications for the management of obesity in adults
Walmsley R, Sumithran P |
The Medical Journal of Australia | 2023 |
|
NPFF Decreases Activity of Human Arcuate NPY Neurons: A Study in Embryonic-Stem-Cell-Derived Model
L Torz, K Niss, S Lundh, J Rekling, C Quintana, S Frazier, A Mercer, A Cornea, C Bertelsen, M Gerstenberg, A Hansen, M Guldbrandt, J Lykkesfeldt, L John, J Villaescusa, N Petersen |
International journal of molecular sciences | 2022 |
|
Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review
M Mahapatra, M Karuppasamy, B Sahoo |
Pharmaceutical Research | 2022 |
|
An Overview of the TRP-Oxidative Stress Axis in Metabolic Syndrome: Insights for Novel Therapeutic Approaches
M Araújo, S Soczek, J Pontes, L Marques, G Santos, G Simão, L Bueno, D Maria-Ferreira, M Muscará, E Fernandes |
Cells | 2022 |
|
Neuroprotective Effects of a Cholecystokinin Analogue in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Parkinson’s Disease Mouse Model
Z Zhang, H Li, Y Su, J Ma, Y Yuan, Z Yu, M Shi, S Shao, Z Zhang, C Hölscher |
Frontiers in neuroscience | 2022 |
|
Lipidated PrRP31 metabolites are long acting dual GPR10 and NPFF2 receptor agonists with potent body weight lowering effect
F Alexopoulou, E Bech, S Pedersen, D Thorbek, U Leurs, L Rudkjær, K Fosgerau, H Hansen, N Vrang, J Jelsing, L Elster |
Scientific Reports | 2022 |
|
The Regulatory Role of the Central and Peripheral Serotonin Network on Feeding Signals in Metabolic Diseases
K Nonogaki |
International journal of molecular sciences | 2022 |
|
The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
M Klausen, M Thomsen, G Wortwein, A FinkJensen |
British Journal of Pharmacology | 2022 |
|
Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients
T Masaki, Y Ozeki, Y Yoshida, M Okamoto, S Miyamoto, K Gotoh, H Shibata |
Metabolites | 2022 |
|
Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria
C Loreto, V Minarelli, G Nasini, R Norgiolini, P Sindaco |
Diabetes Therapy | 2022 |
|
Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists
R Song, H Qian, Y Wang, Q Li, D Li, J Chen, J Yang, J Zhong, H Yang, X Min, H Xu, Y Yang, J Chen, T Masaki |
Journal of Diabetes Research | 2022 |
|
Metabolic factors in the regulation of hypothalamic innate immune responses in obesity
A Folick, R Cheang, M Valdearcos, S Koliwad |
Experimental & molecular medicine | 2022 |
|
Digital Brain Maps and Virtual Neuroscience: An Emerging Role for Light-Sheet Fluorescence Microscopy in Drug Development
J Perens, J Hecksher-Sørensen |
Frontiers in neuroscience | 2022 |
|
Expanded LUXendin Color Palette for GLP1R Detection and Visualization In Vitro and In Vivo
J Ast, A Novak, T Podewin, N Fine, B Jones, A Tomas, R Birke, K Roßmann, B Mathes, J Eichhorst, M Lehmann, A Linnemann, D Hodson, J Broichhagen |
2022 | |
|
Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes
C van Ruiten, D Veltman, A Schrantee, L van Bloemendaal, F Barkhof, M Kramer, M Nieuwdorp, R IJzerman |
The Journal of clinical endocrinology and metabolism | 2022 |
|
Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Mouhammad ZA, Vohra R, Horwitz A, Thein AS, Rovelt J, Cvenkel B, Williams PA, Azuara-Blanco A, Kolko M |
Frontiers in neuroscience | 2022 |
|
MC4R biased signalling and the conformational basis of biological function selections
Liu Z, Hruby VJ |
Journal of Cellular and Molecular Medicine | 2022 |
|
Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress-, and drug-induced heroin-seeking in rats.
Douton JE, Acharya NK, Stoltzfus B, Sun D, Grigson PS, Nyland JE |
Behavioural Pharmacology | 2022 |
|
FTO gene expression in diet-induced obesity is downregulated by Solanum fruit supplementation.
Asuquo EA, Nwodo OFC, Assumpta AC, Orizu UN, Oziamara ON, Solomon OA |
Open Life Sciences | 2022 |
|
Gut microbes and food reward: From the gut to the brain
de Wouters d\u2019Oplinter A, Huwart SJ, Cani PD, Everard A |
Frontiers in neuroscience | 2022 |
|
Hindbrain circuits in the control of eating behaviour and energy balance.
Cheng W, Gordian D, Ludwig MQ, Pers TH, Seeley RJ, Myers MG Jr |
Nature metabolism | 2022 |
|
Effects of Liraglutide on Gastrointestinal Functions and Weight in Obesity: A Randomized Clinical and Pharmacogenomic Trial
Maselli D, Atieh J, Clark MM, Eckert D, Taylor A, Carlson P, Burton DD, Busciglio I, Harmsen WS, Vella A, Acosta A, Camilleri M |
Obesity (Silver Spring, Md.) | 2022 |
|
The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors
Dong M, Wen S, Zhou L |
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy | 2022 |
|
Signaling pathways in obesity: mechanisms and therapeutic interventions.
Wen X, Zhang B, Wu B, Xiao H, Li Z, Li R, Xu X, Li T |
Signal Transduction and Targeted Therapy | 2022 |
|
Treatments for obesity in the context of nonalcoholic steatohepatitis and mental health
Sharma A, Albhaisi S, Sanyal AJ |
Clinical Liver Disease | 2022 |
|
Glucagon‐like peptide‐1 analogues for overweight or obese adults
Madrid E, Ocara Vargas M, Contreras-Vera C, Saldías C, Escobar Liquitay CM, Novik A V, Munoz SR, Bracchiglione J |
The Cochrane Database of Systematic Reviews | 2022 |
|
Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options
Salvatore T, Galiero R, Caturano A, Vetrano E, Loffredo G, Rinaldi L, Catalini C, Gjeloshi K, Albanese G, Di Martino A, Docimo G, Sardu C, Marfella R, Sasso FC |
Biomedicines | 2022 |
|
Effects of the POMC System on Glucose Homeostasis and Potential Therapeutic Targets for Obesity and Diabetes
Yang D, Hou X, Yang G, Li M, Zhang J, Han M, Zhang Y, Liu Y |
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy | 2022 |
|
Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease.
Nowell J, Blunt E, Edison P |
Molecular Psychiatry | 2022 |
|
HypoMap-a unified single-cell gene expression atlas of the murine hypothalamus.
Steuernagel L, Lam BYH, Klemm P, Dowsett GKC, Bauder CA, Tadross JA, Hitschfeld TS, Del Rio Martin A, Chen W, de Solis AJ, Fenselau H, Davidsen P, Cimino I, Kohnke SN, Rimmington D, Coll AP, Beyer A, Yeo GSH, Brüning JC |
Nature metabolism | 2022 |
|
Activation of arcuate nucleus glucagon-like peptide-1 receptor-expressing neurons suppresses food intake.
Singh I, Wang L, Xia B, Liu J, Tahiri A, El Ouaamari A, Wheeler MB, Pang ZP |
Cell & Bioscience | 2022 |
|
Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions.
Imbernon M, Saponaro C, Helms HCC, Duquenne M, Fernandois D, Deligia E, Denis RGP, Chao DHM, Rasika S, Staels B, Pattou F, Pfrieger FW, Brodin B, Luquet S, Bonner C, Prevot V |
Cell Metabolism | 2022 |
|
An olive-derived elenolic acid stimulates hormone release from L-cells and exerts potent beneficial metabolic effects in obese diabetic mice
Wang Y, Wu Y, Wang A, Wang A, Alkhalidy H, Helm R, Zhang S, Ma H, Zhang Y, Gilbert E, Xu B, Liu D |
Frontiers in Nutrition | 2022 |
|
The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury
Pang J, Feng JN, Ling W, Jin T |
Acta pharmaceutica Sinica. B | 2022 |
|
Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis
Bakker W, Imbernon M, Salinas CG, Moro Chao DH, Hassouna R, Morel C, Martin C, Leger C, Denis RG, Castel J, Peter A, Heni M, Maetzler W, Nielsen HS, Duquenne M, Schwaninger M, Lundh S, Johan Hogendorf WF, Gangarossa G, Secher A, Hecksher-Sørensen J, Pedersen TÅ, Prevot V, Luquet S |
Cell Reports | 2022 |
|
Glucagon-like peptide-1 analog liraglutide leads to multiple metabolic alterations in diet-induced obese mice.
Park S, Oh S, Kim EK |
The Journal of biological chemistry | 2022 |
|
Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity.
Diene G, Angulo M, Hale PM, Jepsen CH, Hofman PL, Hokken-Koelega A, Ramesh C, Turan S, Tauber M |
The Journal of clinical endocrinology and metabolism | 2022 |
|
Obesity in Adults: A 2022 Adapted Clinical Practice Guideline for Ireland.
Breen C, O'Connell J, Geoghegan J, O'Shea D, Birney S, Tully L, Gaynor K, O'Kelly M, O'Malley G, O'Donovan C, Lyons O, Flynn M, Allen S, Arthurs N, Browne S, Byrne M, Callaghan S, Collins C, Courtney A, Crotty M, Donohue C, Donovan C, Dunlevy C, Duggan D, Fearon N, Finucane F, Fitzgerald I, Foy S, Garvey J, Gibson I, Glynn L, Gregg E, Griffin A, Harrington JM, Heary C, Heneghan H, Hogan A, Hynes M, Kearney C, Kelly D, Neff K, le Roux CW, Manning S, McAuliffe F, Moore S, Moran N, Murphy M, Murrin C, O'Brien SM, O'Donnell C, O'Dwyer S, O'Grada C, O'Malley E, O'Reilly O, O'Reilly S, Porter O, Roche HM, Rhynehart A, Ryan L, Seery S, Soare C, Shaamile F, Walsh A, Woods C, Woods C, Yoder R |
Obesity facts | 2022 |
|
Liraglutide Counteracts Endoplasmic Reticulum Stress in Palmitate-Treated Hypothalamic Neurons without Restoring Mitochondrial Homeostasis
Griffin H, Sullivan SC, Barger SW, Phelan KD, Baldini G |
International journal of molecular sciences | 2022 |
|
Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression
Wagner S, Brierley DI, Leeson-Payne A, Jiang W, Chianese R, Lam BY, Dowsett GK, Cristiano C, Lyons D, Reimann F, Gribble FM, Martinez de Morentin PB, Yeo GS, Trapp S, Heisler LK |
Molecular Metabolism | 2022 |
|
Growth hormone treatment does not augment the anti‐diabetic effects of liraglutide in UCD‐T2DM rats
Swarbrick MM, Cox CL, Graham JL, Knudsen LB, Stanhope K, Raun K, Havel PJ |
2022 | |
|
A comparative transcriptomic analysis of Glucagon-like peptide-1 receptor- and Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus
Smith C, Patterson-Cross R, Woodward O, Lewis J, Chiarugi D, Merkle F, Gribble F, Reimann F, Adriaenssens A |
Appetite | 2022 |
|
Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial
Wretlind A, Zobel EH, de Zawadzki A, Ripa RS, Curovic VR, von Scholten BJ, Mattila IM, Hansen TW, Kjær A, Vestergaard H, Rossing P, Legido-Quigley C |
Frontiers in Clinical Diabetes and Healthcare | 2022 |
|
Glucocorticoids, stress and eating: The mediating role of appetite-regulating hormones.
Kuckuck S, van der Valk ES, Scheurink AJW, van der Voorn B, Iyer AM, Visser JA, Delhanty PJD, van den Berg SAA, van Rossum EFC |
Obesity reviews : an official journal of the International Association for the Study of Obesity | 2022 |
|
The Significance of Hypothalamic Inflammation and Gliosis for the Pathogenesis of Obesity in Humans
Sewaybricker LE, Huang A, Chandrasekaran S, Melhorn SJ, Schur EA |
Endocrine reviews | 2022 |
|
Adipokines: Deciphering the Cardiovascular Signature of Adipose Tissue: Biochemical Pharmacology Special Issue on Mechanisms of Blood Pressure
Galley JC, Singh S, Awata WM, Alves JV, Bruder-Nascimento T |
Biochemical Pharmacology | 2022 |
|
Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea
Jiang W, Li W, Cheng J, Li W, Cheng F |
Sleep & breathing = Schlaf & Atmung | 2022 |
|
POMC neuronal heterogeneity in energy balance and beyond: an integrated view
C Quarta, M Claret, LM Zeltser, KW Williams, GS Yeo, MH Tschöp, S Diano, JC Brüning, D Cota |
Nature metabolism | 2021 |
|
Hypothalamic GPCR Signaling Pathways in Cardiometabolic Control
Y Deng, G Deng, JL Grobe, H Cui |
Frontiers in physiology | 2021 |
|
A genetic map of the mouse dorsal vagal complex and its role in obesity
MQ Ludwig, W Cheng, D Gordian, J Lee, SJ Paulsen, SN Hansen, KL Egerod, P Barkholt, CJ Rhodes, A Secher, LB Knudsen, C Pyke, MG Myers, TH Pers |
2021 | |
|
Reappraising the role of the vagus nerve in GLP‐1‐mediated regulation of eating
DI Brierley, G Lartigue |
British Journal of Pharmacology | 2021 |
|
Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
S Trapp, DI Brierley |
British Journal of Pharmacology | 2021 |
|
Central and peripheral GLP-1 systems independently suppress eating
DI Brierley, MK Holt, A Singh, A de Araujo, M McDougle, M Vergara, MH Afaghani, SJ Lee, K Scott, C Maske, W Langhans, E Krause, A de Kloet, FM Gribble, F Reimann, L Rinaman, G de Lartigue, S Trapp |
Nature metabolism | 2021 |
|
GLP-1 Suppresses Feeding Behaviors and Modulates Neuronal Electrophysiological Properties in Multiple Brain Regions
XY Chen, L Chen, W Yang, AM Xie |
Frontiers in molecular neuroscience | 2021 |
|
Glucagon‐like peptide‐1 (GLP‐1) signalling in the brain: From neural circuits and metabolism to therapeutics
A Kabahizi, B Wallace, L Lieu, D Chau, Y Dong, E Hwang, K Williams |
British Journal of Pharmacology | 2021 |
|
The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells
A Marzook, A Tomas, B Jones |
Frontiers in Endocrinology | 2021 |
|
Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity
N Marrano, G Biondi, A Borrelli, A Cignarelli, S Perrini, L Laviola, F Giorgino, A Natalicchio |
Biomolecules | 2021 |
|
An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is)
S Wen, T Nguyen, M Gong, X Yuan, C Wang, J Jin, L Zhou |
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy | 2021 |
|
Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
J Michałowska, E Miller-Kasprzak, P Bogdański |
Nutrients | 2021 |
|
GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Basedz Therapies in Treating Metabolic Disorders
RJ Samms, KW Sloop, FM Gribble, F Reimann, AE Adriaenssens |
Diabetes | 2021 |
|
The Gut–Brain Axis and Its Role in Controlling Eating Behavior in Intestinal Inflammation
GW Moran, G Thapaliya |
Nutrients | 2021 |
|
Subcutaneous infusion of neurosecretory protein GL promotes fat accumulation in mice
Y Narimatsu, K Fukumura, E Iwakoshi-Ukena, A Mimura, M Furumitsu, K Ukena |
Heliyon | 2021 |
|
Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo
Y Dong, J Carty, N Goldstein, Z He, E Hwang, D Chau, B Wallace, A Kabahizi, L Lieu, Y Peng, Y Gao, L Hu, JN Betley, KW Williams |
Molecular Metabolism | 2021 |
|
Area Postrema Cell Types that Mediate Nausea-Associated Behaviors
C Zhang, JA Kaye, Z Cai, Y Wang, SL Prescott, SD Liberles |
Neuron | 2021 |
|
Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon‐like peptide‐1 receptor agonists
HN Yassine, V Solomon, A Thakral, N SheikhBahaei, HC Chui, MN Braskie, LS Schneider, K Talbot |
Alzheimer's & dementia : the journal of the Alzheimer's Association | 2021 |
|
The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability
C Girges, N Vijiaratnam, D Athauda, G Auld, S Gandhi, T Foltynie |
Drugs & Aging | 2021 |
|
The Physiological Control of Eating: Signals, Neurons, and Networks
A Watts, S Kanoski, G Sanchez-Watts, W Langhans |
Physiological reviews | 2021 |
|
Sex- and Gender-Based Pharmacological Response to Drugs
F Mauvais-Jarvis, HK Berthold, I Campesi, JJ Carrero, S Dhakal, F Franconi, I Gouni-Berthold, ML Heiman, A Kautzky-Willer, SL Klein, A Murphy, V Regitz-Zagrosek, K Reue, JB Rubin, E Barker |
Pharmacological reviews | 2021 |
|
The role of glia in the physiology and pharmacology of glucagon‐like peptide‐1: implications for obesity, diabetes, neurodegeneration and glaucoma
Q Cui, L Stein, S Fortin, M Hayes |
British Journal of Pharmacology | 2021 |
|
Repurposing GLP-1 Receptor Agonists for Parkinson’s Disease: Current Evidence and Future Opportunities
DB Victorino, M Nejm, M Guimarães-Marques, FA Scorza, CA Scorza |
Pharmaceutical medicine | 2021 |
|
Brain Imaging of the GLP-1 Receptor in Obesity Using 68Ga-NODAGA-Exendin-4 PET
LN Deden, J Booij, J Grandjean, JR Homberg, EJ Hazebroek, M Gotthardt, M Boss |
Brain Sciences | 2021 |
|
Reagents and models for detecting endogenous GLP1R and GIPR
J Ast, J Broichhagen, DJ Hodson |
EBioMedicine | 2021 |
|
Synthesis, Optimization, and Biological Evaluation of Corrinated Conjugates of the GLP-1R Agonist Exendin-4
IC Tinsley, T Borner, MK Swanson, OG Chepurny, SA Doebley, V Kamat, IR Sweet, GG Holz, MR Hayes, BC Jonghe, RP Doyle |
Journal of Medicinal Chemistry | 2021 |
|
The diverse effects of brain glucagon‐like peptide 1 receptors on ingestive behaviour
DL Williams |
British Journal of Pharmacology | 2021 |
|
Actions of glucagon‐like peptide‐1 receptor ligands in the gut
JJ Holst, DB Andersen, KV Grunddal |
British Journal of Pharmacology | 2021 |
|
Single-Cell Mapping of GLP-1 and GIP Receptor Expression in the Dorsal Vagal Complex
MQ Ludwig, PV Todorov, KL Egerod, DP Olson, TH Pers |
Diabetes | 2021 |
|
Expression of glucagon-like peptide 1 receptor in neuropeptide Y neurons of the arcuate nucleus in mice
Y Ruska, A Szilvásy-Szabó, D Kővári, A Kádár, L Mácsai, R Sinkó, E Hrabovszky, B Gereben, C Fekete |
Brain structure & function | 2021 |
|
The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
MR Hayes, T Borner, BC Jonghe |
Diabetes | 2021 |
|
Glucagon‐like peptide‐1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?
T Borner, IC Tinsley, RP Doyle, MR Hayes, BC Jonghe |
British Journal of Pharmacology | 2021 |
|
Whole-brain activation signatures of weight-lowering drugs
HH Hansen, J Perens, U Roostalu, JL Skytte, CG Salinas, P Barkholt, DD Thorbek, KT Rigbolt, N Vrang, J Jelsing, J Hecksher-Sørensen |
Molecular Metabolism | 2021 |
|
Gastrointestinal Distension by Pectin-Containing Carbonated Solution Suppresses Food Intake and Enhances Glucose Tolerance via GLP-1 Secretion and Vagal Afferent Activation
K Ohbayashi, Y Oyama, C Yamaguchi, T Asano, T Yada, Y Iwasaki |
Frontiers in Endocrinology | 2021 |
|
A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors
R Merkel, A Moreno, Y Zhang, R Herman, JB Nathan, S Zeb, S Rahematpura, K Stecyk, BT Milliken, MR Hayes, RP Doyle, HD Schmidt |
Neuroscience and biobehavioral reviews | 2021 |
|
A survey of the mouse hindbrain in the fed and fasted states using single-nucleus RNA sequencing
GK Dowsett, BY Lam, JA Tadross, I Cimino, D Rimmington, AP Coll, J Polex-Wolf, LB Knudsen, C Pyke, GS Yeo |
Molecular Metabolism | 2021 |
|
GLP-1 Induces the Expression of FNDC5 Derivatives That Execute Lipolytic Actions
H Li, W Donelan, F Wang, P Zhang, L Yang, Y Ding, D Tang, S Li |
Frontiers in Cell and Developmental Biology | 2021 |
|
Anatomical and Functional Characterization of Central Amygdala Glucagon-Like Peptide 1 Receptor Expressing Neurons
N Zeng, E Cutts, C Lopez, S Kaur, M Duran, S Virkus, J Hardaway |
Frontiers in behavioral neuroscience | 2021 |
|
GLP-1 and hunger modulate incentive motivation depending on insulin sensitivity in humans
R Hanssen, AC Kretschmer, L Rigoux, K Albus, SE Thanarajah, T Sitnikow, C Melzer, OA Cornely, JC Brüning, M Tittgemeyer |
Molecular Metabolism | 2021 |
|
Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists
J Ard, A Fitch, S Fruh, L Herman |
Advances in Therapy | 2021 |
|
Functionally distinct POMC-expressing neuron subpopulations in hypothalamus revealed by intersectional targeting
N Biglari, I Gaziano, J Schumacher, J Radermacher, L Paeger, P Klemm, W Chen, S Corneliussen, CM Wunderlich, M Sue, S Vollmar, T Klöckener, T Sotelo-Hitschfeld, A Abbasloo, F Edenhofer, F Reimann, FM Gribble, H Fenselau, P Kloppenburg, FT Wunderlich, JC Brüning |
Nature Neuroscience | 2021 |
|
Clinical Impact of Liraglutide as a Treatment of Obesity
H Alruwaili, B Dehestani, CW le Roux |
Clinical pharmacology : advances and applications | 2021 |
|
A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
MC Tilinca, RA Tiuca, A Burlacu, A Varga |
Medicina | 2021 |
|
Behavioural and neurochemical mechanisms underpinning the feeding-suppressive effect of GLP-1/CCK combinatorial therapy
E Roth, S Benoit, B Quentin, B Lam, S Will, M Ma, N Heeley, T Darwish, Y Shrestha, F Gribble, F Reimann, I Pshenichnaya, G Yeo, DJ Baker, JL Trevaskis, C Blouet |
Molecular Metabolism | 2021 |
|
Case Report: Bilateral Ciliary Body Detachment in a Patient Taking Oral Diet Pills
Y Li, Y Tao, X Gao, F Yu |
Optometry and Vision Science | 2021 |
|
Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide
DR Kamm, KD Pyles, MC Sharpe, LN Healy, JR Colca, KS McCommis |
The Journal of biological chemistry | 2021 |
|
Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY3-36 Combination Therapy in Diet-Induced Obese Rats
U Dischinger, J Hasinger, M Königsrainer, C Corteville, C Otto, M Fassnacht, M Hankir, FJ Seyfried |
Frontiers in Endocrinology | 2021 |
|
Potential gut–brain mechanisms behind adverse mental health outcomes of bariatric surgery
RM Brown, E Guerrero-Hreins, WA Brown, CW le Roux, P Sumithran |
Nature Reviews Endocrinology | 2021 |
|
The Role of the Gut Microbiota in the Gut–Brain Axis in Obesity: Mechanisms and Future Implications
J van Son, LL Koekkoek, SE Fleur, MJ Serlie, M Nieuwdorp |
International journal of molecular sciences | 2021 |
|
MRI measures of hypothalamic injury are associated with glucagon‐like peptide‐1 receptor agonist treatment response in people with hypothalamic obesity
FA Perez, C Elfers, JA Yanovski, AH Shoemaker, MJ Abuzzahab, CL Roth |
Diabetes, obesity & metabolism | 2021 |
|
Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis
K Vosoughi, J Atieh, L Khanna, K Khoshbin, LJ Prokop, P Davitkov, MH Murad, M Camilleri |
2021 | |
|
Roux-en-Y Gastric Bypass and Caloric Restriction but Not Gut Hormone-Based Treatments Profoundly Impact the Hypothalamic Transcriptome in Obese Rats
U Dischinger, T Heckel, T Bischler, J Hasinger, M Königsrainer, A Schmitt-Böhrer, C Otto, M Fassnacht, F Seyfried, M Hankir |
Nutrients | 2021 |
|
Amylin as a Future Obesity Treatment
B Dehestani, N Stratford, C le Roux |
Journal of Obesity & Metabolic Syndrome | 2021 |
|
GLP-1 physiology informs the pharmacotherapy of obesity
D Drucker |
Molecular Metabolism | 2021 |
|
The melanocortin pathway and energy homeostasis: From discovery to obesity therapy
Yeo GS, Chao DH, Siegert AM, Koerperich ZM, Ericson MD, Simonds SE, Larson CM, Luquet S, Clarke I, Sharma S, Clément K, Cowley MA, Haskell-Luevano C, Van Der Ploeg L, Adan RA |
Molecular Metabolism | 2021 |
|
The incretin/glucagon system as a target for pharmacotherapy of obesity.
Del Prato S, Gallwitz B, Holst JJ, Meier JJ |
Obesity reviews : an official journal of the International Association for the Study of Obesity | 2021 |
|
Effects of glucagon‐like peptide‐1 analogue treatment in genetic obesity: A case series
Welling MS, de Groot CJ, Kleinendorst L, van der Voorn B, Burgerhart JS, van der Valk ES, van Haelst MM, van den Akker EL, van Rossum EF |
Clinical Obesity | 2021 |
|
Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats
Douton JE, Horvath N, Mills-Huffnagle S, Nyland JE, Hajnal A, Grigson PS |
Addiction Biology | 2021 |
|
Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia
Mariana Igoillo-Esteve, Ana F Oliveira, Cristina Cosentino, Federica Fantuzzi, Céline Demarez, Sanna Toivonen, Amélie Hu, Satyan Chintawar, Miguel Lopes, Nathalie Pachera, Ying Cai, Baroj Abdulkarim, Myriam Rai, Lorella Marselli, Piero Marchetti, Mohammad Tariq, Jean-Christophe Jonas, Marina Boscolo, Massimo Pandolfo, Decio Eizirik, Miriam Cnop |
JCI Insight | 2020 |
|
Semaglutide lowers body weight in rodents via distributed neural pathways
Sanaz Gabery, Casper G. Salinas, Sarah J. Paulsen, Jonas Ahnfelt-Rønne, Tomas Alanentalo, Arian F. Baquero, Stephen T. Buckley, Erzsébet Farkas, Csaba Fekete, Klaus S Frederiksen, Hans Christian C. Helms, Jacob Jeppesen, Linu M. John, Charles Pyke, Jane Nøhr, Tess T. Lu, Joseph Polex-Wolf, Vincent Prevot, Kirsten Raun, Lotte Simonsen, Gao Sun, Anett Szilvásy-Szabó, Hanni Willenbrock, Anna Secher, Lotte Bjerre Knudsen |
JCI Insight | 2020 |
|
Leptin receptor-expressing Nucleus Tractus Solitarius neurons suppress food intake independently of GLP1 in mice
Wenwen Cheng, Ermelinda Ndoka, Chelsea R. Hutch, Karen Roelofs, Andrew Mackinnon, Basma Khoury, Irwin J. Magrisso, Ki-Suk Kim, Christopher J. Rhodes, David P. Olson, Randy J. Seeley, Darleen A. Sandoval, Martin G. Myers Jr. |
JCI Insight | 2020 |
|
Calcitonin Receptor Neurons in the Mouse Nucleus Tractus Solitarius Control Energy Balance via the Non-aversive Suppression of Feeding
W Cheng, I Gonzalez, W Pan, AH Tsang, J Adams, E Ndoka, D Gordian, B Khoury, K Roelofs, SS Evers, A MacKinnon, S Wu, H Frikke-Schmidt, JN Flak, JL Trevaskis, CJ Rhodes, S Fukada, RJ Seeley, DA Sandoval, DP Olson, C Blouet, MG Myers |
Cell Metabolism | 2020 |
|
A Role for GLP-1 in Treating Hyperphagia and Obesity
HJ Grill |
Endocrinology | 2020 |
|
PPG neurons in the nucleus of the solitary tract modulate heart rate but do not mediate GLP-1 receptor agonist-induced tachycardia in mice
MK Holt, DR Cook, DI Brierley, JE Richards, F Reimann, AV Gourine, N Marina, S Trapp |
Molecular Metabolism | 2020 |
|
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
BA McLean, CK Wong, JE Campbell, DJ Hodson, S Trapp, DJ Drucker |
Endocrine reviews | 2020 |
|
Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats
VN Marty, M Farokhnia, JJ Munier, Y Mulpuri, L Leggio, I Spigelman |
Frontiers in neuroscience | 2020 |
|
Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
Y Diz-Chaves, S Herrera-Pérez, LC González-Matías, JA Lamas, F Mallo |
Nutrients | 2020 |
|
GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
EW Iepsen, CT Have, S Veedfald, S Madsbad, JJ Holst, N Grarup, O Pedersen, I Brandslund, JC Holm, T Hansen, SS Torekov |
Reproduction | 2020 |
|
Childhood obesity and the associated rise in cardiometabolic complications
S Caprio, N Santoro, R Weiss |
Nature metabolism | 2020 |
|
GLP-1 mediated diuresis and natriuresis are blunted in heart failure and restored by selective afferent renal denervation
K Katsurada, SS Nandi, H Zheng, X Liu, NM Sharma, KP Patel |
Cardiovascular Diabetology | 2020 |
|
GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats
SM Fortin, RK Lipsky, R Lhamo, J Chen, E Kim, T Borner, HD Schmidt, MR Hayes |
Science Translational Medicine | 2020 |
|
Effects of metabolic state on the regulation of melanocortin circuits
L Lieu, D Chau, S Afrin, Y Dong, AL Alhadeff, JN Betley, KW Williams |
Physiology & Behavior | 2020 |
|
GLP-1 Receptor Signaling in Astrocytes Regulates Fatty Acid Oxidation, Mitochondrial Integrity, and Function
K Timper, A del Río-Martín, AL Cremer, S Bremser, J Alber, P Giavalisco, L Varela, C Heilinger, H Nolte, A Trifunovic, TL Horvath, P Kloppenburg, H Backes, JC Brüning |
Cell Metabolism | 2020 |
|
Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis
T Borner, JL Workinger, IC Tinsley, SM Fortin, LM Stein, OG Chepurny, GG Holz, AJ Wierzba, D Gryko, E Nexø, ED Shaulson, A Bamezai, VA Silva, BC Jonghe, MR Hayes, RP Doyle |
Cell Reports | 2020 |
|
A second‐generation glucagon‐like peptide‐1 receptor agonist mitigates vomiting and anorexia while retaining glucoregulatory potency in lean diabetic and emetic mammalian models
T Borner, ED Shaulson, IC Tinsley, LM Stein, CC Horn, MR Hayes, RP Doyle, BC Jonghe |
Diabetes, obesity & metabolism | 2020 |
|
Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer’s and Parkinson’s disease therapeutics
TS Salameh, EM Rhea, K Talbot, WA Banks |
Biochemical Pharmacology | 2020 |
|
Diagnosis, Background, and Treatment of Hypothalamic Damage in Craniopharyngioma
EM Erfurth |
Neuroendocrinology | 2020 |
|
Hypothalamic Pomc expression restricted to GABAergic neurons suppresses Npy overexpression and restores food intake in obese mice
M Trotta, EP Bello, R Alsina, MB Tavella, JL Ferrán, M Rubinstein, VF Bumaschny |
Molecular Metabolism | 2020 |
|
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
MA Nauck, DR Quast, J Wefers, JJ Meier |
Molecular Metabolism | 2020 |
|
Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists
M Lucey, P Pickford, S Bitsi, J Minnion, J Ungewiss, K Schoeneberg, GA Rutter, SR Bloom, A Tomas, B Jones |
Molecular Metabolism | 2020 |
|
Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes
C Gibbons, J Blundell, ST Hoff, K Dahl, R Bauer, T Bækdal |
Diabetes, obesity & metabolism | 2020 |
|
Leveraging the Gut to Treat Metabolic Disease
RE Gimeno, DA Briere, RJ Seeley |
Cell Metabolism | 2020 |
|
Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics
J Ast, A Arvaniti, NH Fine, D Nasteska, FB Ashford, Z Stamataki, Z Koszegi, A Bacon, BJ Jones, MA Lucey, S Sasaki, DI Brierley, B Hastoy, A Tomas, G DAgostino, F Reimann, FC Lynn, CA Reissaus, AK Linnemann, E DEste, D Calebiro, S Trapp, K Johnsson, T Podewin, J Broichhagen, DJ Hodson |
Nature Communications | 2020 |
|
Hindbrain melanocortin 3/4 receptors modulate the food intake and body weight suppressive effects of the GLP-1 receptor agonist, liraglutide
SM Fortin, J Chen, MR Hayes |
Physiology & Behavior | 2020 |
|
Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus
JH Bae, HJ Choi, KI Cho, LK Kim, JS Kwon, YM Cho |
Diabetes & Metabolism Journal | 2020 |
|
Brain Endothelial Cells Regulate Glucagon-Like Peptide 1 Entry Into the Brain via a Receptor-Mediated Process
Z Fu, L Gong, J Liu, J Wu, EJ Barrett, KW Aylor, Z Liu |
Frontiers in physiology | 2020 |
|
Reframing appetitive reinforcement learning and reward valuation as effects mediated by hippocampal-dependent behavioral inhibition
S Jones, A Hyde, TL Davidson |
Nutrition research (New York, N.Y.) | 2020 |
|
Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats
D Vallöf, AL Kalafateli, E Jerlhag |
Translational Psychiatry | 2020 |
|
Current Long-Term Pharmacotherapies for the Management of Obesity
BY Kim, SM Kang, JH Kang, KK Kim, B Kim, SJ Kim, YH Kim, JH Kim, JH Kim, GE Nam, JY Park, JW Son, HJ Shin, TJ Oh, H Lee, EJ Jeon, S Chung, YH Hong, CH Kim |
Journal of Obesity & Metabolic Syndrome | 2020 |
|
An Optimized Mouse Brain Atlas for Automated Mapping and Quantification of Neuronal Activity Using iDISCO+ and Light Sheet Fluorescence Microscopy
J Perens, CG Salinas, JL Skytte, U Roostalu, AB Dahl, TB Dyrby, F Wichern, P Barkholt, N Vrang, J Jelsing, J Hecksher-Sørensen |
Neuroinformatics | 2020 |
|
Brain Site-Specific Inhibitory Effects of the GLP-1 Analogue Exendin-4 on Alcohol Intake and Operant Responding for Palatable Food
KJ Colvin, HS Killen, MJ Kanter, MC Halperin, L Engel, PJ Currie |
International journal of molecular sciences | 2020 |
|
Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain
E Farkas, A Szilvásy-Szabó, Y Ruska, R Sinkó, MG Rasch, T Egebjerg, C Pyke, B Gereben, LB Knudsen, C Fekete |
Brain structure & function | 2020 |
|
Comprehensive Review of Current and Upcoming Anti-Obesity Drugs
JW Son, S Kim |
Diabetes & Metabolism Journal | 2020 |
|
A phase 3 randomized clinical trial using a o nce‐weekly glucagon‐like peptide‐1 receptor agonist in adolescents and young adults with hypothalamic obesity
CL Roth, FA Perez, KB Whitlock, C Elfers, JA Yanovski, AH Shoemaker, MJ Abuzzahab |
Diabetes, obesity & metabolism | 2020 |
|
L’obésité chez l’adulte : ligne directrice de pratique clinique
S Wharton, DC Lau, M Vallis, AM Sharma, L Biertho, D Campbell-Scherer, K Adamo, A Alberga, R Bell, N Boulé, E Boyling, J Brown, B Calam, C Clarke, L Crowshoe, D Divalentino, M Forhan, Y Freedhoff, M Gagner, S Glazer, C Grand, M Green, M Hahn, R Hawa, R Henderson, D Hong, P Hung, I Janssen, K Jacklin, C Johnson-Stoklossa, A Kemp, S Kirk, J Kuk, MF Langlois, S Lear, A McInnes, D Macklin, L Naji, P Manjoo, MP Morin, K Nerenberg, I Patton, S Pedersen, L Pereira, H Piccinini-Vallis, M Poddar, P Poirier, D Prudhomme, XR Salas, C Rueda-Clausen, S Russell-Mayhew, J Shiau, D Sherifali, J Sievenpiper, S Sockalingam, V Taylor, E Toth, L Twells, R Tytus, S Walji, L Walker, S Wicklum |
CMAJ : Canadian Medical Association Journal | 2020 |
|
Obesity in adults: a clinical practice guideline
S Wharton, DC Lau, M Vallis, AM Sharma, L Biertho, D Campbell-Scherer, K Adamo, A Alberga, R Bell, N Boulé, E Boyling, J Brown, B Calam, C Clarke, L Crowshoe, D Divalentino, M Forhan, Y Freedhoff, M Gagner, S Glazer, C Grand, M Green, M Hahn, R Hawa, R Henderson, D Hong, P Hung, I Janssen, K Jacklin, C Johnson-Stoklossa, A Kemp, S Kirk, J Kuk, MF Langlois, S Lear, A McInnes, D Macklin, L Naji, P Manjoo, MP Morin, K Nerenberg, I Patton, S Pedersen, L Pereira, H Piccinini-Vallis, M Poddar, P Poirier, D Prudhomme, XR Salas, C Rueda-Clausen, S Russell-Mayhew, J Shiau, D Sherifali, J Sievenpiper, S Sockalingam, V Taylor, E Toth, L Twells, R Tytus, S Walji, L Walker, S Wicklum |
CMAJ : Canadian Medical Association Journal | 2020 |
|
A systematic review on different models of inducing obesity in animals: Advantages and limitations
J Suleiman, M Mohamed, A Bakar |
2020 | |
|
CNS-targeting pharmacological interventions for the metabolic syndrome
Kerstin Stemmer, Timo D. Müller, Richard DiMarchi, Paul T. Pfluger, Matthias H. Tschoep |
Journal of Clinical Investigation | 2019 |
|
The Role of Glucagon-Like Peptide-1 in Energy Homeostasis
M Salehi, JQ Purnell |
Metabolic Syndrome and Related Disorders | 2019 |
|
The Discovery and Development of Liraglutide and Semaglutide
LB Knudsen, J Lau |
Frontiers in Endocrinology | 2019 |
|
Glucagon-like peptide 1 (GLP-1)
TD Müller, B Finan, SR Bloom, D D'Alessio, DJ Drucker, PR Flatt, A Fritsche, F Gribble, HJ Grill, JF Habener, JJ Holst, W Langhans, JJ Meier, MA Nauck, D Perez-Tilve, A Pocai, F Reimann, DA Sandoval, TW Schwartz, RJ Seeley, K Stemmer, M Tang-Christensen, SC Woods, RD DiMarchi, MH Tschöp |
Molecular Metabolism | 2019 |
|
Central Glucagon-like Peptide-1 Receptor Signaling via Brainstem Catecholamine Neurons Counteracts Hypertension in Spontaneously Hypertensive Rats
K Katsurada, M Nakata, T Saito, B Zhang, Y Maejima, SS Nandi, NM Sharma, KP Patel, K Kario, T Yada |
Scientific Reports | 2019 |
|
Does glucagon-like peptide-1 induce diuresis and natriuresis by modulating afferent renal nerve activity?
K Katsurada, SS Nandi, NM Sharma, H Zheng, X Liu, KP Patel |
American journal of physiology. Renal physiology | 2019 |
|
Is the Brain a Key Player in Glucose Regulation and Development of Type 2 Diabetes?
MH Lundqvist, K Almby, N Abrahamsson, JW Eriksson |
Frontiers in physiology | 2019 |
|
Preclinical Assessment of Leptin Transport into the Cerebrospinal Fluid in Diet‐Induced Obese Minipigs
A Chmielewski, T Hubert, A Descamps, D Mazur, M Daoudi, P Ciofi, C Fontaine, R Caiazzo, F Pattou, V Prevot, M Pigeyre |
Obesity | 2019 |
|
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
AE Adriaenssens, EK Biggs, T Darwish, J Tadross, T Sukthankar, M Girish, J Polex-Wolf, BY Lam, I Zvetkova, W Pan, D Chiarugi, GS Yeo, C Blouet, FM Gribble, F Reimann |
Cell Metabolism | 2019 |
|
The Regulation of Peripheral Metabolism by Gut-Derived Hormones
EW Sun, AM Martin, RL Young, DJ Keating |
Frontiers in Endocrinology | 2019 |
|
Central GLP-1 receptors: Novel molecular targets for cocaine use disorder
NS Hernandez, HD Schmidt |
Physiology & Behavior | 2019 |
|
Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons – Implications for energy balance and glucose control
Z He, Y Gao, L Lieu, S Afrin, J Cao, NJ Michael, Y Dong, J Sun, H Guo, KW Williams |
Molecular Metabolism | 2019 |
|
Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
LB Knudsen |
2019 | |
|
Long-acting glucagon-like peptide-1 receptor agonist—status December 2018
JJ Holst |
Annals of translational medicine | 2019 |
|
Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes
CS Hansen, CS Frandsen, J Fleischer, D Vistisen, JJ Holst, L Tarnow, FK Knop, S Madsbad, HU Andersen, TF Dejgaard |
Frontiers in Endocrinology | 2019 |
|
Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway
C Ratner, Z He, KV Grunddal, LJ Skov, B Hartmann, F Zhang, A Feuchtinger, A Bjerregaard, C Christoffersen, MH Tschöp, B Finan, RD DiMarchi, GM Leinninger, KW Williams, C Clemmensen, B Holst |
Diabetes | 2019 |
|
Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease
KS Hershon, BR Hirsch, O Odugbesan |
Clinical diabetes : a publication of the American Diabetes Association | 2019 |
|
Incretin-Based Antihyperglycemic Agents for the Management of Acute Ischemic Stroke in Patients with Diabetes Mellitus: A Review
D Milonas, T Didangelos, AI Hatzitolios, K Tziomalos |
Diabetes Therapy | 2019 |
|
Interleukin‐6 in the central amygdala is bioactive and co‐localised with glucagon‐like peptide‐1 receptor
F Anesten, AD Gasull, JE Richard, I Farkas, D Mishra, L Taing, F Zhang, M Poutanen, V Palsdottir, Z Liposits, KP Skibicka, JO Jansson |
Journal of Neuroendocrinology | 2019 |
|
GLP-1: Molecular mechanisms and outcomes of a complex signaling system
NK Smith, TA Hackett, A Galli, CR Flynn |
Neurochemistry International | 2019 |
|
Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
RM Christensen, CR Juhl, SS Torekov |
Drug Safety | 2019 |
|
Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea
KK Kim |
Korean Journal of Family Medicine | 2019 |
|
Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss
CG Liberini, K Koch-Laskowski, E Shaulson, LE McGrath, RK Lipsky, R Lhamo, M Ghidewon, T Ling, LM Stein, MR Hayes |
Scientific Reports | 2019 |
|
The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis
Q Que, X Guo, L Zhan, S Chen, Z Zhang, X Ni, B Ye, S Wan |
Journal of Inflammation | 2019 |
|
Cardiovascular risk and obesity
C Cercato, FA Fonseca |
Diabetology & metabolic syndrome | 2019 |
|
GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve
H Ueno, R Ito, S Abe, H Ogino, M Maruyama, H Miyashita, Y Miyamoto, Y Moritoh, Y Tsujihata, K Takeuchi, N Nishigaki, T Alquier |
PloS one | 2019 |
|
GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity
H Kadouh, V Chedid, H Halawi, DD Burton, MM Clark, D Khemani, A Vella, A Acosta, M Camilleri |
The Journal of clinical endocrinology and metabolism | 2019 |
|
Liraglutide Modulates Appetite and Body Weight Via GLP-1R-Expressing Glutamatergic Neurons
JM Adams, H Pei, DA Sandoval, RJ Seeley, RB Chang, SD Liberles, DP Olson |
Diabetes | 2018 |
|
Loss of dorsomedial hypothalamic GLP-1 signaling reduces BAT thermogenesis and increases adiposity
SJ Lee, G Sanchez-Watts, JP Krieger, A Pignalosa, PN Norell, A Cortella, KG Pettersen, D Vrdoljak, MR Hayes, S Kanoski, W Langhans, AG Watts |
Molecular Metabolism | 2018 |
|
Translating biased signaling in the ghrelin receptor system into differential in vivo functions
F Mende, C Hundahl, B Plouffe, LJ Skov, B Sivertsen, AN Madsen, M Lückmann, TA Diep, S Offermanns, TM Frimurer, M Bouvier, B Holst |
Proceedings of the National Academy of Sciences | 2018 |
|
Pharmacological Interventions for Obesity: Current and Future Targets
ME Bocarsly |
Current Addiction Reports | 2018 |
|
GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose
Y Iwasaki, M Sendo, K Dezaki, T Hira, T Sato, M Nakata, C Goswami, R Aoki, T Arai, P Kumari, M Hayakawa, C Masuda, T Okada, H Hara, DJ Drucker, Y Yamada, M Tokuda, T Yada |
Nature Communications | 2018 |
|
Glucagon-like peptide-1 regulates brown adipose tissue thermogenesis via the gut-brain axis in rats
JP Krieger, EP da Conceição, G Sanchez-Watts, M Arnold, KG Pettersen, M Mohammed, S Modica, P Lossel, SF Morrison, CJ Madden, AG Watts, W Langhans, SJ Lee |
American Journal of Physiology - Regulatory, Integrative and Comparative Physiology | 2018 |
|
A vitamin B12 conjugate of exendin-4 improves glucose tolerance without associated nausea or hypophagia in rodents
EG Mietlicki-Baase, CG Liberini, JL Workinger, RL Bonaccorso, T Borner, DJ Reiner, K Koch-Laskowski, LE McGrath, R Lhamo, LM Stein, BC Jonghe, GG Holz, CL Roth, RP Doyle, MR Hayes |
Diabetes, obesity & metabolism | 2018 |
|
Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
S Paternoster, M Falasca |
Frontiers in Endocrinology | 2018 |
|
Targeting GLP-1 receptor trafficking to improve agonist efficacy
B Jones, T Buenaventura, N Kanda, P Chabosseau, BM Owen, R Scott, R Goldin, N Angkathunyakul, IR Corrêa, D Bosco, PR Johnson, L Piemonti, P Marchetti, AM Shapiro, BJ Cochran, AC Hanyaloglu, A Inoue, T Tan, GA Rutter, A Tomas, SR Bloom |
Nature Communications | 2018 |
|
Food Perception Primes Hepatic ER Homeostasis via Melanocortin-Dependent Control of mTOR Activation
C Brandt, H Nolte, S Henschke, LE Ruud, M Awazawa, DA Morgan, P Gabel, HG Sprenger, ME Hess, S Günther, T Langer, K Rahmouni, H Fenselau, M Krüger, JC Brüning |
Cell | 2018 |
|
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
J Rowlands, J Heng, P Newsholme, R Carlessi |
Frontiers in Endocrinology | 2018 |
|
Enterochromaffin 5-HT cells – A major target for GLP-1 and gut microbial metabolites
ML Lund, KL Egerod, MS Engelstoft, O Dmytriyeva, E Theodorsson, BA Patel, TW Schwartz |
Molecular Metabolism | 2018 |
|
Integrated Brain Atlas for Unbiased Mapping of Nervous System Effects Following Liraglutide Treatment
CB Salinas, TT Lu, S Gabery, K Marstal, T Alanentalo, AJ Mercer, A Cornea, K Conradsen, J Hecksher-Sørensen, AB Dahl, LB Knudsen, A Secher |
Scientific Reports | 2018 |
|
Neuroendocrine response to GABA-B receptor agonism in alcohol-dependent individuals: Results from a combined outpatient and human laboratory experiment
M Farokhnia, MB Sheskier, MR Lee, AN Le, E Singley, S Bouhlal, T Ton, Z Zhao, L Leggio |
Neuropharmacology | 2018 |
|
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
B Ahrén, SL Atkin, G Charpentier, ML Warren, JP Wilding, S Birch, AG Holst, LA Leiter |
Diabetes, obesity & metabolism | 2018 |
|
Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study
N Otowa-Suematsu, K Sakaguchi, T Nakamura, K Hara, M Kishi, N Hashimoto, K Yokota, H Yoshino, Y Kuroki, T Nishiumi, A Sou, H Komada, Y Okada, Y Hirota, Y Tamori, W Ogawa |
Diabetes Therapy | 2018 |
|
Why Weight? An Analytic Review of Obesity Management, Diabetes Prevention, and Cardiovascular Risk Reduction
LI Igel, KH Saunders, JJ Fins |
Current Atherosclerosis Reports | 2018 |
|
A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota
L Zhao, Y Chen, F Xia, B Abudukerimu, W Zhang, Y Guo, N Wang, Y Lu |
Frontiers in Endocrinology | 2018 |
|
A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice
DC Hornigold, E Roth, V Howard, S Will, S Oldham, MP Coghlan, C Blouet, JL Trevaskis |
Appetite | 2018 |
|
Battle of GLP-1 delivery technologies
M Yu, MM Benjamin, S Srinivasan, EE Morin, EI Shishatskaya, SP Schwendeman, A Schwendeman |
Advanced Drug Delivery Reviews | 2018 |
|
Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials
A Tanaka, K Node |
Cardiovascular Diabetology | 2018 |
|
Beyond Glucagon-like Peptide-1: Is G-Protein Coupled Receptor Polypharmacology the Path Forward to Treating Metabolic Diseases?
KW Sloop, DA Briere, PJ Emmerson, FS Willard |
2018 | |
|
Chemical Strategies for Half-Life Extension of Biopharmaceuticals: Lipidation and Its Alternatives
EM Bech, SL Pedersen, KJ Jensen |
ACS Medicinal Chemistry Letters | 2018 |
|
Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events?
CF Murphy, CW le Roux |
Annals of translational medicine | 2018 |
|
Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys
M Thomsen, JJ Holst, A Molander, K Linnet, M Ptito, A Fink-Jensen |
Psychopharmacology | 2018 |
|
Mouse Gcg Neuron Activation Reduces Food Intake and Body Weight
Ronald Gaykema, brandon newmyer, matteo ottolini, Vidisha Raje, Daniel M. Warthen, Philip Lambeth, Maria Niccum, Ting Yao, yiru huang, Ira Schulman, Thurl Harris, manoj patel, kevin williams, Michael M. Scott |
Journal of Clinical Investigation | 2017 |
|
PC1/3 Deficiency Impacts Pro-opiomelanocortin Processing in Human Embryonic Stem Cell-Derived Hypothalamic Neurons
L Wang, L Sui, SK Panigrahi, K Meece, Y Xin, J Kim, J Gromada, CA Doege, SL Wardlaw, D Egli, RL Leibel |
Stem Cell Reports | 2017 |
|
Ghrelin, CCK, GLP-1, and PYY(3–36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB
RE Steinert, C Feinle-Bisset, L Asarian, M Horowitz, C Beglinger, N Geary |
Physiological reviews | 2017 |
|
Anxiety, Depression, and the Microbiome: A Role for Gut Peptides
G Lach, H Schellekens, TG Dinan, JF Cryan |
Neurotherapeutics | 2017 |
|
Toward a Wiring Diagram Understanding of Appetite Control
ML Andermann, BB Lowell |
Neuron | 2017 |
|
Enhanced AMPA Receptor Trafficking Mediates the Anorexigenic Effect of Endogenous Glucagon-like Peptide-1 in the Paraventricular Hypothalamus
J Liu, K Conde, P Zhang, V Lilascharoen, Z Xu, BK Lim, RJ Seeley, JJ Zhu, MM Scott, ZP Pang |
Neuron | 2017 |
|
The dynamic plasticity of insulin production in β-cells
BB Boland, CJ Rhodes, JS Grimsby |
Molecular Metabolism | 2017 |
|
Liraglutide modulates GABAergic signaling in rat hippocampal CA3 pyramidal neurons predominantly by presynaptic mechanism
O Babateen, SV Korol, Z Jin, AK Bhandage, A Ahemaiti, B Birnir |
BMC Pharmacology and Toxicology | 2017 |
|
Acute activation of GLP-1-expressing neurons promotes glucose homeostasis and insulin sensitivity
X Shi, S Chacko, F Li, D Li, D Burrin, L Chan, X Guan |
Molecular Metabolism | 2017 |
|
Exendin-4 reduces food intake via the PI3K/AKT signaling pathway in the hypothalamus
Y Yang, PP Choi, WW Smith, W Xu, D Ma, ZA Cordner, NC Liang, TH Moran |
Scientific Reports | 2017 |
|
Appetite Regulation: Hormones, Peptides, and Neurotransmitters and Their Role in Obesity
GD Miller |
American journal of lifestyle medicine | 2017 |
|
Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides
R Sekar, L Wang, BK Chow |
Frontiers in Endocrinology | 2017 |
|
Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential
ME Røder |
Therapeutic Advances in Chronic Disease | 2017 |
|
Beneficial effects of liraglutide (GLP1 analog) in the hippocampal inflammation
AR Barreto-Vianna, MB Aguila, CA Mandarim-de-Lacerda |
Metabolic Brain Disease | 2017 |
|
Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system
K Kaineder, T Birngruber, G Rauter, B Obermüller, J Eichler, J Münzker, W Al-Zoughbi, SI Mautner, SS Torekov, B Hartmann, P Kotzbeck, TR Pieber |
International Journal of Obesity | 2017 |
|
Gut Microbiota-Dependent Modulation of Energy Metabolism
CN Heiss, LE Olofsson |
Journal of Innate Immunity | 2017 |
|
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
B Geloneze, JC de Lima-Júnior, LA Velloso |
Drugs | 2017 |
|
GLP-1R Signaling Directly Activates Arcuate Nucleus Kisspeptin Action in Brain Slices but Does not Rescue Luteinizing Hormone Inhibition in Ovariectomized Mice During Negative Energy Balance
KM Heppner, AF Baquero, CM Bennett, SR Lindsley, MA Kirigiti, B Bennett, MA Bosch, AJ Mercer, OK Rønnekleiv, C True, KL Grove, MS Smith |
eNeuro | 2017 |
|
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
S Lee, DY Lee |
Annals of Pediatric Endocrinology & Metabolism | 2017 |
|
The Obesity–Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients
A Sfera, C Osorio, LA Inderias, V Parker, AI Price, M Cummings |
Frontiers in Psychiatry | 2017 |
|
Heterogeneity of hypothalamic pro-opiomelanocortin-expressing neurons revealed by single-cell RNA sequencing
BY Lam, I Cimino, J Polex-Wolf, SN Kohnke, D Rimmington, V Iyemere, N Heeley, C Cossetti, R Schulte, LR Saraiva, DW Logan, C Blouet, S O'Rahilly, AP Coll, GS Yeo |
Molecular Metabolism | 2017 |
|
Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?
CA Roberts, P Christiansen, JC Halford |
Acta Diabetologica | 2017 |
|
Control of Food Intake by Gastrointestinal Peptides: Mechanisms of Action and Possible Modulation in the Treatment of Obesity
P Prinz, A Stengel |
Journal of Neurogastroenterology and Motility | 2017 |
|
The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg
MC Mancini, ME de Melo |
Diabetology & metabolic syndrome | 2017 |
|
Paraventricular Thalamic Control of Food Intake and Reward: Role of Glucagon-Like Peptide-1 Receptor Signaling
ZY Ong, JJ Liu, ZP Pang, HJ Grill |
Neuropsychopharmacology | 2017 |
|
Response: Regulating Hypothalamus Gene Expression in Food Intake: Dietary Composition or Calorie Density? ( Diabetes Metab J 2017;41:121-7)
M Jang, SY Park, YW Kim, SP Jung, JY Kim |
Diabetes & Metabolism Journal | 2017 |
|
Letter: Regulating Hypothalamus Gene Expression in Food Intake: Dietary Composition or Calorie Density? ( Diabetes Metab J 2017;41:121-7)
BK Koo |
Diabetes & Metabolism Journal | 2017 |
|
Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment
M Gejl, B Brock, L Egefjord, K Vang, J Rungby, A Gjedde |
Scientific Reports | 2017 |
|
The glucagon-like peptide-1 receptor in the ventromedial hypothalamus reduces short-term food intake in male mice by regulating nutrient sensor activity
MA Burmeister, JD Brown, JE Ayala, DA Stoffers, DA Sandoval, RJ Seeley, JE Ayala |
American journal of physiology. Endocrinology and metabolism | 2017 |
|
Semaglutide seems to be more effective the other GLP-1Ras
JJ Holst, S Madsbad |
Annals of translational medicine | 2017 |
|
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial
M Davies, TR Pieber, ML Hartoft-Nielsen, OK Hansen, S Jabbour, J Rosenstock |
Journal of the American Medical Association | 2017 |
|
Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
Y Seino, Y Terauchi, T Osonoi, D Yabe, N Abe, T Nishida, J Zacho, S Kaneko |
Diabetes, obesity & metabolism | 2017 |
|
Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons
NB Dalsgaard, T Vilsbøll, FK Knop |
Diabetes, obesity & metabolism | 2017 |
|
Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice
T Kaisho, H Nagai, T Asakawa, N Suzuki, H Fujita, K Matsumiya, N Nishizawa, Y Kanematsu-Yamaki, K Dote, J Sakamoto, T Asami, S Takekawa |
International Journal of Obesity | 2017 |
|
Limiting glucocorticoid secretion increases the anorexigenic property of Exendin-4
SJ Lee, K Diener, S Kaufman, JP Krieger, KG Pettersen, N Jejelava, M Arnold, AG Watts, W Langhans |
Molecular Metabolism | 2016 |
|
Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist
K Katsurada, T Yada |
Journal of Diabetes Investigation | 2016 |
|
The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice
MA Burmeister, JE Ayala, H Smouse, A Landivar-Rocha, JD Brown, DJ Drucker, DA Stoffers, DA Sandoval, RJ Seeley, JE Ayala |
Diabetes | 2016 |
|
Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
A Anandhakrishnan, M Korbonits |
World journal of diabetes | 2016 |
|
G protein-coupled receptors as targets for anti-diabetic therapeutics
DY Oh, JM Olefsky |
Nature Reviews Drug Discovery | 2016 |
|
Glucagon-Like Peptide-1 Excites Firing and Increases GABAergic Miniature Postsynaptic Currents (mPSCs) in Gonadotropin-Releasing Hormone (GnRH) Neurons of the Male Mice via Activation of Nitric Oxide (NO) and Suppression of Endocannabinoid Signaling Pathways
I Farkas, C Vastagh, E Farkas, F Bálint, K Skrapits, E Hrabovszky, C Fekete, Z Liposits |
Frontiers in cellular neuroscience | 2016 |
|
The incretin hormone glucagon-like peptide 1 increases mitral cell excitability by decreasing conductance of a voltage-dependent potassium channel: GLP-1 modulation in the olfactory bulb
N Thiebaud, IJ Llewellyn-Smith, F Gribble, F Reimann, S Trapp, DA Fadool |
The Journal of Physiology | 2016 |
|
GLP-1 and weight loss: unraveling the diverse neural circuitry
SE Kanoski, MR Hayes, KP Skibicka |
American Journal of Physiology - Regulatory, Integrative and Comparative Physiology | 2016 |
|
The Gut as an Endocrine Organ: Role in the Regulation of Food Intake and Body Weight
A Melvin, CW le Roux, NG Docherty |
Current Atherosclerosis Reports | 2016 |
|
Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro
E Zhu, Y Yang, J Zhang, Y Li, C Li, L Chen, B Sun |
Oncotarget | 2016 |
|
Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease
HH Hansen, K Fabricius, P Barkholt, P Kongsbak-Wismann, C Schlumberger, J Jelsing, D Terwel, A Termont, C Pyke, LB Knudsen, N Vrang, J Padmanabhan |
PloS one | 2016 |
|
Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus
LB Knudsen, A Secher, J Hecksher-Sørensen, C Pyke |
Journal of Diabetes Investigation | 2016 |
|
Hindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea
BC de Jonghe, RA Holland, DR Olivos, LE Rupprecht, SE Kanoski, MR Hayes |
Physiology & Behavior | 2016 |
|
Extrapancreatic effects of incretin hormones: evidence for weight‐independent changes in morphological aspects and oxidative status in insulin‐sensitive organs of the obese nondiabetic Zucker rat (ZFR)
IM Colin, H Colin, I Dufour, CE Gielen, MC Many, J Saey, B Knoops, AC Gérard |
Physiological Reports | 2016 |
|
Astrocytes Regulate GLP-1 Receptor-Mediated Effects on Energy Balance
DJ Reiner, EG Mietlicki-Baase, LE McGrath, DJ Zimmer, KK Bence, GL Sousa, VR Konanur, J Krawczyk, DH Burk, SE Kanoski, GE Hermann, RC Rogers, MR Hayes |
The Journal of neuroscience : the official journal of the Society for Neuroscience | 2016 |
|
Endogenous Glucagon-like Peptide-1 Receptor Signaling in the Nucleus Tractus Solitarius is Required for Food Intake Control
AL Alhadeff, BD Mergler, DJ Zimmer, CA Turner, DJ Reiner, HD Schmidt, HJ Grill, MR Hayes |
Neuropsychopharmacology | 2016 |
|
Alterations in hypothalamic gene expression following Roux-en-Y gastric bypass
P Barkholt, PJ Pedersen, A Hay-Schmidt, J Jelsing, HH Hansen, N Vrang |
Molecular Metabolism | 2016 |
|
Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis
RV Overgaard, KC Petri, LV Jacobsen, CB Jensen |
Clinical Pharmacokinetics | 2016 |
|
Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review
AM Bodnaruc, D Prudhomme, R Blanchet, I Giroux |
Nutrition & Metabolism | 2016 |
|
Circulating GLP-1 in infants born small-for-gestational-age: breast-feeding versus formula-feeding
M Díaz, J Bassols, G Sebastiani, A López-Bermejo, L Ibáñez, F Zegher |
International Journal of Obesity | 2015 |
|
The L-cell in nutritional sensing and the regulation of appetite
E Spreckley |
Frontiers in Nutrition | 2015 |
|
Neural Control of Energy Balance: Translating Circuits to Therapies
L Gautron, JK Elmquist, KW Williams |
Cell | 2015 |
|
Expression and Distribution of Glucagon-Like Peptide-1 Receptor mRNA, Protein and Binding in the Male Nonhuman Primate ( Macaca mulatta ) Brain
KM Heppner, M Kirigiti, A Secher, SJ Paulsen, R Buckingham, C Pyke, LB Knudsen, N Vrang, KL Grove |
Endocrinology | 2015 |
|
PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation
S Trapp, SC Cork |
American Journal of Physiology - Regulatory, Integrative and Comparative Physiology | 2015 |
|
GLP-1 based therapeutics: simultaneously combating T2DM and obesity
KM Heppner, D Perez-Tilve |
Frontiers in neuroscience | 2015 |
|
Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice
KM Heppner, S Marks, J Holland, N Ottaway, D Smiley, R Dimarchi, D Perez-Tilve |
Diabetologia | 2015 |
|
Endogenous Glucagon-like Peptide-1 Suppresses High-Fat Food Intake by Reducing Synaptic Drive onto Mesolimbic Dopamine Neurons
XF Wang, JJ Liu, J Xia, J Liu, V Mirabella, ZP Pang |
Cell Reports | 2015 |
|
The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer’s Disease
HH Hansen, K Fabricius, P Barkholt, ML Niehoff, JE Morley, J Jelsing, C Pyke, LB Knudsen, SA Farr, N Vrang |
Journal of Alzheimer's disease : JAD | 2015 |
|
Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes
JS Kulve, DJ Veltman, L Bloemendaal, F Barkhof, CF Deacon, JJ Holst, RJ Konrad, JH Sloan, ML Drent, M Diamant, RG IJzerman |
Diabetologia | 2015 |
|
Hypothalamic Obesity in Craniopharyngioma Patients: Disturbed Energy Homeostasis Related to Extent of Hypothalamic Damage and Its Implication for Obesity Intervention
C Roth |
Journal of Clinical Medicine | 2015 |
|
Liraglutide, leptin and their combined effects on feeding: additive intake reduction through common intracellular signalling mechanisms
SE Kanoski, ZY Ong, SM Fortin, ES Schlessinger, HJ Grill |
Diabetes Obesity and Metabolism | 2015 |
|
Albiglutide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
HA Blair, GM Keating |
Drugs | 2015 |
|
Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes
D Ito, T Iuchi, S Kurihara, I Inoue, S Katayama, K Inukai |
Journal of clinical medicine research | 2015 |
|
The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents: Liraglutide and alcohol
D Vallöf, P Maccioni, G Colombo, M Mandrapa, JW Jörnulf, E Egecioglu, JA Engel, E Jerlhag |
Addiction Biology | 2015 |
|
Intestinal GLP-1 and satiation: from man to rodents and back
RE Steinert, C Beglinger, W Langhans |
International Journal of Obesity | 2015 |
|
Glucagon-Like Peptide-1 Receptor Activation in the Ventral Tegmental Area Decreases the Reinforcing Efficacy of Cocaine
HD Schmidt, EG Mietlicki-Baase, KY Ige, JJ Maurer, DJ Reiner, DJ Zimmer, DS van Nest, LA Guercio, ME Wimmer, DR Olivos, BC de Jonghe, MR Hayes |
Neuropsychopharmacology | 2015 |
|
Effects of sleeve gastrectomy and gastric banding on the hypothalamic feeding center in an obese rat model
T Kawasaki, M Ohta, Y Kawano, T Masuda, K Gotoh, M Inomata, S Kitano |
Surgery Today | 2015 |
|
Liraglutide and obesity: a review of the data so far
E Ladenheim |
Drug design, development and therapy | 2015 |
|
Preservation of the Blood Brain Barrier and Cortical Neuronal Tissue by Liraglutide, a Long Acting Glucagon-Like-1 Analogue, after Experimental Traumatic Brain Injury
J Hakon, K Ruscher, B Romner, G Tomasevic, C Holscher |
PloS one | 2015 |
|
Liraglutide: A Review of Its Use in the Management of Obesity
LJ Scott |
Drugs | 2015 |
|
Liraglutide Improves Hypertension and Metabolic Perturbation in a Rat Model of Polycystic Ovarian Syndrome
V Hoang, J Bi, SM Mohankumar, AK Vyas, JA Joles |
PloS one | 2015 |
|
Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes
M Christensen, AH Sparre-Ulrich, B Hartmann, U Grevstad, MM Rosenkilde, JJ Holst, T Vilsbøll, FK Knop |
International Journal of Obesity | 2015 |
|
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
S Madsbad |
Diabetes Obesity and Metabolism | 2015 |
|
Beta cell specific probing with fluorescent exendin-4 is progressively reduced in type 2 diabetic mouse models
J Lehtonen, L Schäffer, MG Rasch, J Hecksher-Sørensen, J Ahnfelt-Rønne |
Islets | 2015 |
|
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
J Crane, B McGowan |
Therapeutic Advances in Chronic Disease | 2015 |
|
CCK Response Deficiency in Synphilin-1 Transgenic Mice
WW Smith, M Smith, D Yang, PP Choi, A Moghadam, T Li, TH Moran, F Blachier |
PloS one | 2015 |
|
GLP-1 and Amylin in the Treatment of Obesity
T Jorsal, J Rungby, FK Knop, T Vilsbøll |
Current Diabetes Reports | 2015 |
|
Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight
Laurie Baggio, Daniel Drucker |
Journal of Clinical Investigation | 2014 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)